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Introduction 
 INTRODUCTION 
 
 HIV infection is one of the most common health problems in 
modern world. Neuropsychological impairments are well 
described in patients with HIV infection from very early days.  
Prior to the antiretroviral therapy, HIV infection causing AIDS 
leading to dementia was high and the cumulative risk of 
developing  HIV associated dementia was estimated between 15 – 
20% in 1993.  In the era of highly active anti retroviral therapy 
(HAART), the clinical spectrum of neuropsychological impairment 
changed from severe HIV associated dementia in advanced AIDS 
to more minor forms of neuropsychological  impairment which 
can be managed with adequate therapy with ART and other 
supportive therapies. 
 Early identification of asymptomatic neuropsychologically 
impaired patients by means of neurologic examination and 
neuropsychological  assessment will be useful in the prevention 
and (or) reduction of neuropsychological impairment in their 
every day functioning of life.   
 The neuropsychological decline in HIV patients occur in all 
stages of infections and it may be modified by factors like ART.  So 
there is a growing need to find out prevalence of 
neuropsychological impairment and types of neuropsychological 
impairment in patients with HIV infection and to find out factors 
that will influence the occurance of neuropsychological 
impairment.  Modification of factors that will influence 
neuropsychological impairment may help to improve the outcome 
of neuropsychological impairment in this HIV infected patients on 
ART. 
 
 
 
 
 
 
 
 
Aim of the study 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 AIMS OF THE STUDY 
 
1. To assess the prevalence of neuropsychological impairment   
among HIV positive patients on  AntiRetroviral 
Therapy(ART). 
 
2. To study the pattern of neuropsychological impairment in 
the    study   population. 
 
3. To study  the factors that may influence the occurance of  
          neuropsychological  impairment  in HIV positive  patients on   
          ART . 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Review of literature 
                                REVIEW OF LITERATURE 
 
 HIV is a globally present most common sexually transmitted 
disease in humans.  Infection with Human Immuno deficiency 
Virus type 1 (HIV-1) cause severe damage to immune system 
thereby causing severe immuno deficiency state leading to 
increased chances of acquiring opportunistic infections and 
malignancies.  HIV infection affects  almost all systems of the 
body. 
 HIV is a  neurotropic virus that invades the brain directly 
shortly after infection.  HIV replicates in macrophages and 
microglia, thereby causing  inflammatory and neurotoxic host 
responses.  Persistent  infection and inflammation of nervous 
system by HIV-1 infection leads to chronic HIV-1 infection causing 
dysfunction in both central nervous system and peripheral 
nervous systems.  Chronic HIV-1 infection can result in 
neurodegenerative disease causing cognitive, behavioural and 
motor difficulties. 
 The neuropsychological impairments caused by HIV-1 
infection includes decreased attention/concentration, 
psychomotor speed, memory, learning, information processing  
and executive function.  There is also motor slowing,  
incoordination, and tremor, that may progress to disabling 
weakness, spasticity, extrapyramidal movement  disorders and 
paraparesis. 
Epidemiology of HIV infection: 
 According to UNAIDS 2011 report, at the end of 2010, an 
estimated 34 million people were living with HIV  globally, 
including 3.4million children less than 15 years.  There was 2.7 
million new HIV infection in 2010, including 3,90,000 among 
children less than 15 years. 
 Globally, the annual number of people newly infected with 
HIV continues to decline, although  there is stark regional 
variation.  In sub Saharan Africa, where most of the people newly 
infected with HIV live, an estimated 1.9 million people become 
infected in 2010.  This was 16% fewer than the estimated 2.2 
million people newly infected with HIV in 2001. 
 The annual number of people dying from AIDS related 
causes  worldwide is steadily decreasing from a peak of 2.2 million 
in 2005 to an estimated 1.8million in 2010.  The number of  people 
dying from AIDS related causes began to decline in 2005-2006 in 
sub-Saharan Africa, South and South East Asia and the Caribbean 
and has continued subsequently. 
 HIV epidemic in India is concentrated in nature.  The HIV 
prevalence among the High Risk Groups ie, female sex workers, 
injecting drug users, men who have sex with  men and 
transgenders is about  20 times higher than the general  
population.(NACO ANNUAL REPORT-2011).  Analysis of 
epidemic projections revealed that the number of new annual HIV 
infections had declined by more than 50 percent during the last 
decade, 2.7 lakh in 2000 to 1.2 lakh in 2009. 
 The estimated adult HIV prevalence in India was 0.32% 
(0.26% - 0.41%) in 2008 and 0.31% (0.25 – 0.39%) in 2009.  The adult 
prevalence is 0.25 percent among women and 0.36 percent among  
men in 2009. 
 The total number of people living with HIV / AIDS (PLHA) 
in India is estimated at 23.9 lakh (19.3 – 30.4 lakh) in 2009. 
 Children under 15 years account for 3.5 percent of all 
infections, while 83 percent are in age group 15 – 49 years.  Of all 
HIV infections, 39 percent (9.3 lakh) are among women.  The four 
high prevalence states of South India (Andra Pradesh -5 lakh; 
Maharastra 4.2 lakh) Karnataka -2.5 lakhs, Tamilnadu -1.5 lakh) 
account for 55 percent of all HIV infections in the country. 
 In Tamilnadu, there are 40 ART centers.  Total number of 
adult  PLHA receiving ART is 45,179 and total number of pediatric 
PLHA receiving ART is 2,776.  Totally 47,955 patients are getting 
ART in Tamilnadu as on Dec 2010. 
 In India adults 3,61,889 patients and pediatric patients 22,837 
are on ART as on Dec 2010. 
CD4 cell count and ART: 
 In Tirunelveli Medical College Hospital, ART Centre was 
started in the year 2005.  Till the  end of 2011, totally 5515 patients 
were registered in the ART centre of which 2325 patients were 
enrolled for ART treatment.  During this more than 6 years of ART 
service, 1099 patients died.    Initially ART was started when CD4 
count falls below 200 cells / mm3.  From 13th April 2009, it was 
revised to 250 cells /mm3.  From November 2011 onwards, NACO 
advised to issue ART, when CD4 count is less than 350 cells/ mm3.  
So more number of patients with HIV will receive ART and HIV 
infection related morbidity and mortality can be reduced. 
Global epidemiology of HIV and (HAND) HIV 
associated, Neuropsychological disorders: 
 HIV is an important global disease,  especially affecting 
sexually active, working populations of the  society.  HIV is 
affecting approximately 34 million people all over the world.  Most 
of the people infected (or) affected by HIV live in developing 
countries.  Africa and the Middle East countries account for over 
two thirds (>66%) of world wide HIV infections, Asia for over 
20%, Eastern Europe and Central  Asia for approximately  4% and 
Latin America and the Caribbean for around 6% (Hemelaar et al 
2006). 
 The rapid evolution of the virus itself has led to considerable 
genetic variation in a relatively short period.  In West Central 
Africa,  almost all of the  nine major subtypes of HIV-1 group M 
(A-D, F-H, J and K) as well as strains of HIV-1 groups N and O, 
and HIV-2 can be found.  In other parts of Africa and other regions 
of the world however, certain subtypes and recombinant forms 
such as CRF 01_AE and CRF 02_AG predominate over others 
(Hemelaar et al 2006). 
 
Neuropathology: 
 HIV-1 enters the CNS early during the course of infection 
(An et al 1999; Davis et al 1992) and causing significant loss of 
nervous and neuronal processes and frequently results in 
neurological disorders with cognitive, motor and  behavioral 
symptoms.  The significant  loss of nervous and neuronal 
processes (eg. Dendritic complexity) in people dying of AIDS 
clearly correlates with ante-mortem neuropsychological 
impairment (Masliah et al 1992; Mattson et al 2005). 
 Cells primarily infected by HIV in CNS are blood derived 
macrophages, resident microglia,  and astrocytes, but most studies 
suggest that neurons are not directly infected (Epstein and 
Gendelman 1993; Trillo-Pazo et al 2003). 
 The Neuronal damage occurs in HIV  infection is due to shed 
viral proteins such as gp 120 (Dreyer et al 1990) and Tat (Jones et 
al 1998; Natts et al 1999; Betmisch et al 2004) (or) indirectly 
through neurotoxic molecules released by activated astrocytes    
(Nath et al 1999) macrophages and microglia.  (Mattson et al 2005; 
Hammerle et al 2005). 
 HIV infection in the brain has widespread and also variable 
effects.  It appears to preferentially cause damage to the basal 
ganglia and deep white matter (Navia et al 1986a).  However, HIV 
infection causing damage to cortical and sub cortical neurons 
(hippocampus and putamen), particularly with  dendritic 
pathology can also likely to play a role in CNS disease 
manifestations. 
Nomenclature: 
 Navia et al initially recommended the term AIDS Dementia 
Complex to label the severe neuropsychological loss and 
neurological dysfunction associated with advanced 
immunodeficiency (Navia et al 1986b).  Then, the American 
Academy of Neurology suggested HIV Associated Dementia as a 
better label (AAN 1991).  Patients with some degree of cognitive 
impairment but whom did not meet criteria for dementia were 
classified as having Minor cognitive motor disorder in the AAN 
nomenclature. 
 With true HIV Associated Dementia,  patient profile were 
marked by severe behavioral changes,  attention and executive 
dysfunction, psychomotor slowing and memory impairment 
(Bornstein et al 1993; Stem et al 2001).  Minor cognitive motor 
disorder patient profiles were characterized by impaired cognitive 
and motor speed, working memory and new learning, but many 
aspects of language (except fluency) and long term (semantic) 
memory  were relatively unimpaired. 
 For research and epidemiological purposes HIV Associated 
Neuropsychological Disorders (HAND) be used as a more 
comprehensive titles with three broad subdivisions depending on 
the degree of cognitive  impairment and its impact on every day 
functioning. 
 
 
 
a) Asymptomatic Neuro cognitive Impairment (ANI) 
 ANI is defined by  decline in performance by at least 1 
standard deviation (SD) below the mean of demographically 
adjusted normative scores in at least two cognitive areas 
(Attention-working memory, speed of information processing, 
language, abstraction – executive function, complex motor skills, 
memory including learning and recall, simple motor skills, (or) 
sensory perceptual abilities), but without any apparent changes in 
activities of daily living. 
b) Mild Neuropsychological Disorder (MND) 
 It is previously referred as minor cognitive and motor 
disorder, features the same test performance criteria as above, but 
with notable changes (at least mild) in activities of daily living. 
c) HIV Associated Dementia (HAD) 
 It requires decline in performance by  atleast 2 SD below 
demographically  corrected normative means in at least two 
different cognitive areas,  as well as marked difficulty in activities 
of daily living due to cognitive impairment  (Antinori et al 2007). 
 Diagnosis of all three forms of HAND also requires a 
determination that the observed neuropsychological impairment 
and / or functional disturbance cannot be explained by co-morbid 
(non HIV related) conditions. 
 Now the severe forms of HAND are far less common, this 
classification system  has been geared more towards mild and 
even asymptomatic impairment.  As a  consequence the new 
system may give better estimates of  neuropsychological disorders 
than AIDS Dementia Complex. 
 This updated classification system, based on both 
neuropsychological test performance and its effects on day to day 
activities (including activities of daily  living and functional 
abilities).   
Patterns of Neuropsychological Dysfunction: 
 Human Immuno deficiency Virus infection characteristically 
produces a "sub-cortical" pattern of neuropsychological 
dysfunction with deficits predominantly seen in executive 
functions, attention and working memory, motor speed, speed of 
information processing, new learning and retrieval of new 
information, while long term (semantic) memory, many language 
skills, and visuo-spatial abilities may remain intact (Dawes et al 
2008; Grount et al 1987; Heaton et al 1995). 
 This average pattern of neuropsychological impairment 
reported by numerous studies before and after the advent of 
highly active anti retroviral therapy, has helped in the 
development of various test batteries which are also presently  
used in the  assessment of neuropsychological functions in HIV 
patients. 
 It is rare to have HIV infected people without comorbidities 
in most parts of the world.  Excluding  comorbidities, especially in 
resource limited countries like sub-Saharan Africa, makes the 
sample less representative of the broader HIV-infected 
populations, but it gives more confidence that any impairment 
discovered on examination is directly due to HIV.  Also, the 
prevalence and impact of various comorbid clinical conditions 
may vary across various international countries. 
HIV Associated Neuropsychological Disorders in 
Developed and Developing countries: 
 Prior to era of highly active anti retroviral therapy, the 
cumulative risk of developing HIV associated dementia was about 
15 – 20% (Mc Arthur et al 1993).  Incidence of HIV dementia in the 
MACS cohort was estimated to decrease by 53% from 21.1 per 1000 
person years between 1990 to 1992, to 10.5 per 1000 persons years 
between  1996 to 1998 (Sacktor et al 2001). 
 The clinical spectrum of the disease has shifted from the 
severe and devastating form of dementia commonly seen in 
association with advanced AIDS (end stage disease) before the 
introduction of protease inhibitors and highly active anti retroviral 
therapy (HAART) , to the milder and more manageable forms of 
HAND. 
 More recent studies conducted in patients on HAART,  
estimate that the prevalence of neuro cognitive dysfunction (based 
on neuropsychological assessments) in HIV populations ranges 
from 20 – 37% even with treatment (Robertson et al 2007b; 
Sacktor et al 2001;).  The CHARTER study group recently 
presented findings from comprehensive neuropsychological 
evaluations lasting from 2 to 2.5 hours on a large unselected 
population of 1,555 HIV positive patients and reported that, 
overall, 45% of cohort had neuropsychological impairment, based 
on a global neuro psychological rating (Heaton et al 2009). 
 The most remarkable outcome following the introduction of 
protease inhibitor (PI) and combination therapy was the dramatic 
decrease in CNS opportunistic diseases such as cryptococcal 
meningitis, cerebral toxoplasmosis,  primary CNS lymphoma and 
progressive multifocal leukoencephalopathy (d’Arminio  
Monforte et al 2004).  In poor countries these opportunitic CNS 
diseases and CNS infections by Mycobacterium tuberculosis, 
plasmodium species and other  pathogens remain common. 
 The prevalence of HIV-Associated Dementia in sub-Saharan 
Africa has been reported to be from as low as 3% to as high as 54%.  
(Howlett et al 1989) at least in a part due to differences in 
definition and  methods used. 
 Clifford et al (2007) report that International HIV Dementia 
Scale,  a brief screening tool, did not detect any significant  
differences in cognitive status between HIV positive and negative  
subjects in Ethiopia consistent with clinical impression (Clifford et 
al 2007).  Contrastingly, studies in India, China and Uganda 
reported  prevalence rates of 56%, 34%, and 31% respectively 
(Heaton et al 2008; Robertson et al 2007a ; Yepthomi et al 2006).  
HIV-1 sub type C predominates  in India, subtype B and CRF 01-
AE in China, and sub types A and D in Uganda. 
 In a larger study of former plasma donors in rural China,  
Heaton et al (2008) administered the international test battery to 
203 HIV positives and 198 HIV negative adults, mostly farmers 
(mean education = 5 – 6 years)  (Heaton et al 2008) and results 
showed 37% of HIV positive group as impaired based on 
neuropsychological assessments. 
 Another study which evaluated the pattern of 
neuropsychological performance in a sample of HIV positive 
patients and HIV negative control subjects in Uganda showed 
significant group differences on measures of verbal learning  and 
memory, speed of information processing, attention and executive 
functioning  (Robertson et al 2007a). 
 Gupta et al. (2007) compared a sample of 119 adults in India  
infected with HIV-1 sub type C who were not on antiretroviral 
therapy, with normative data derived from an  Indian sample of 
540 healthy volunteers (with comparable gender distribution, age, 
and education) and with a matched cohort of 126 healthy, HIV-1 – 
seronegative individuals  (Gupta et al.2007).   They found a high 
rate (60.5%) of mild to moderate cognitive deficits in the HIV 
patients  but no evidence of true dementia.  The 
neuropsychological  profile was characterized by deficits in 
fluency, working memory, and learning and memory, once again 
similar to patterns that have been observed in the West. 
 A study reporting HIV-1 subtype-associated differences in 
neurological disease  was recently reported by Sacktor et al (2007).   
 In the first randomized clinical trial observing 
neuropsychological effects of antiretroviral treatment  in treatment 
naïve patients from multiple resources limited settings,  Robertson 
et al. (2009) found substantial improvement across multiple time 
points of follow up from week 24 out to week 96 across seven 
resource limited setting countries (Robertson et al. 2009).  The 
analysis was limited to 293 participants who were randomized to 
treatment  with didanosine enteric-coated (ddI) + emtricitabine 
(FTC) + atazanavir (ATV) in the AIDS Clinical Trials Group 
(ACTG) Study A5175 (PEARLS) , and did not include groups on 
alternate treatment regimens or untreated control groups for 
comparison. 
 Significant improvements in neuropsychological functioning 
after initiating antiretroviral therapy were determined after 
controlling for baseline function, age, sex, country, CD4, plasma 
HIV-1 RNA strain, and years of education.  Notably, the 
magnitude of improvement in neuropsychological  functioning 
varied across the countries and could not be explained by systemic 
disease factors.  Improved neuropsychological functioning  may be 
due to control of HIV viral load through antiretroviral therapy 
effects,  uncontrolled practice effects on repeated  test 
administrations or both.  
STAGING 
 HIV disease staging and classification systems are critical 
tools for tracking and monitoring the HIV epidemic and clinical 
management.  Two major classification systems currently are in 
use: the U.S. Centers for Disease Control and Prevention (CDC) 
classification system and the World Health Organization (WHO) 
Clinical Staging and Disease Classification System. 
 The CDC disease staging system assesses the severity of HIV  
disease by CD4 cell counts and by the presence of specific HIV-
related conditions.  The definition of AIDS  includes all HIV-
infected individuals with CD4 counts of <200 cells/μL (or CD4 
percentage <14%) as well as those with certain HIV-related 
conditions and symptoms.  The CDC system is used in clinical and 
epidemiologic research. 
 In contrast to the CDC system, the WHO Clinical Staging 
and Disease Classification System (revised in 2005) can be used 
readily in resource-constrained  settings without access to CD4 cell 
count measurements or other diagnostic and laboratory testing 
methods.  The WHO system classifies HIV disease on the basis of 
clinical manifestations that can be recognized and treated by 
clinicians in diverse settings,  including  resource-constrained  
settings, and by clinicians with varying levels of HIV expertise and 
training. 
 
 
 
 
 
 
 
 
 
 
 
 
CDC Classifications System for HIV Infection 
 The CDC categorization of HIV/AIDS is based on the lowest 
documented CD4 cell count (Table 1) and on previously diagnosed 
HIV-related conditions (Tables 2 and 3).  For example, if a patient 
had a condition that once met the criteria for Category B but now 
is asymptomatic, the patient would remain in Category B.  
Additionally, categorization is based on specific conditions, as 
indicated below.  Patients in categories A3, B3, and C1-C3 are 
considered to  have AIDS. 
Table 1.  CDC Classification System for HIV-Infected Adults 
and Adolescents. 
 Clinical Categories 
CD4 Cell 
Categories  
A 
Asymptomatic, 
Acute HIV, or PGL 
(Persistant 
generalized 
lymphadenopathy) 
B 
Symptomatic 
Conditions, not 
A or C 
C 
AIDS-Indicator 
Conditions 
(1) ≥500cells/μL A1 B1 C1 
(2)200-499 cells/μL A2 B2 C2 
(3) <200 cells/μL A3 B3 C3 
 
 
 
 
 
 
 
Table 2. CDC Classification System : Category B Symptomatic 
Conditions 
Category B symptomatic conditions are defined as symptomatic 
conditions occurring in an HIV-infected adolescent or adult those 
meet at least 1 of the following criteria: 
a) They are attributed to HIV infection or indicate a
defect in cell-mediated immunity. 
b) They are considered to have a clinical course or
management that is complicated by HIV infection. 
Examples include, but are not limited to, the following: 
- Bacillary angiomatosis 
- Oropharyngeal candidiasis (thrush) 
- Vulvovaginal candidiasis, persistent or resistant 
- Pelvic inflammatory disease (PID) 
- Cervical dysplasia (moderate or severe) / cervical carcinoma 
situ 
- Hairy leukoplakia, oral 
- Idiopathic thrombocytopenic purpura 
- Constitutional symptoms, such as fever (>38.50C) or diarrhea 
lasting >1 month 
- Peripheral  neuropathy 
- Herpes zoster (Shingles), involving ≥2 episodes or ≥1 
dermatome  
 
 
 
 
Table 3. CDC Classification System : Category C AIDS-Indicator 
Conditions 
- Bacterial pneumonia, recurrent (≥ 2 episodes in 12 months) 
- Candidiasis of the bronchi. Trachea, or lungs 
- Candidiasis, esophageal   
- Cervical  carcinoma, invasive, confirmed by biopsy  
- Coccidioidomycosis, disseminated or extrapulmonary 
- Cryptococcosis, extrapulmonary 
- Cryptosporidiosis, chronic intestinal (>1-month duration) 
- Cytomegalovirus disease (other than liver, spleen, or nodes) 
- Encephalopathy, HIV-related 
- Herpes simplex : Chronic ulcers (>1-month duration), or bronchitis, 
pneumonitis, or esophagitis 
- Histoplasmosis, disseminated or extrapulmonary 
- Isosporiasis, chronic intestinal (>1-month duration) 
- Kaposi sarcoma 
- Lymphoma, Burkitt, immunoblastic, or primary central nervous
system 
- Mycobacterium avium complex (MAC) or M kansasii, disseminated or
extrapulmonary  
- Mycobacterium tuberculosis, pulmonary or extrapulmonary 
- Mycobacterium, other species or unidentified species,  disseminated or
extrapulmonary  
- Pneumocystis jiroveci (formerly carinii) pneumonia (PCP) 
- Progressive multifocal leukoencephalopathy (PML) 
- Salmonella septicemia, recurrent (nontyphoid) 
- Toxoplasmosis of brain 
- Wasting syndrome due to HIV (involuntary weight loss >10% of 
baseline body weight) associated with either chronic diarrhea (≥2 loose 
stools per day ≥1 month) or chronic weakness and documented fever 
≥1 month 
 
WHO  Clinical Staging of HIV / AIDS and Case Definition 
. The clinical staging and case definition of HIV for resource-constrained 
settings were developed by the WHO in 1990 and revised in 2007.  For the
purpose of the WHO staging system,  adolescents and adults are defined as
individuals aged ≥15 years. 
Clinical Stage I:   
. Asymptomatic 
. Persistent generalized lymphadenopathy 
Clinical Stage II: 
• Moderate unexplained * weight loss (under 10% of presumed or
measured body weight)** 
• Recurrent respiratory tract infections (sinusitis, tonsillitis, otitis media,
pharyngitis) 
• Herpes zoster 
• Angular chelitis 
• Recurrent oral ulceration 
• Papular pruritic eruptions 
• Seborrhoeic dermatitis 
• Fungal nail infections 
Clinical Stage III: 
• Unexplained* severe weight loss (over 10% of presumed or measured
body weight)* 
• Unexplained* chronic diarrhea for longer than one month 
• Unexplained* persistent fever (intermittent or constant for longer that
one month) 
• Persistent oral candidiasis   
 
 
• Oral hairy leukoplakia 
• Pulmonary tuberculosis 
• Severe bacterial infections (e.g. pneumonia, empyema, pyomyositis,
bone or joint infection, meningitis, bacteraemia) 
• Acute necrotizing ulcerative stomatitis, gingivitis or periodontitis 
• Unexplained* anaemia (below 8g/dl), neutropenia (below 0.5 billion/l)
and / or chronic thrombocytopenia (below 50 billion/l) 
Clinical stage IV: 
• HIV wasting syndrome 
• Pneumocystis pneumonia 
• Recurrent severe bacterial pneumonia 
• Chronic herpes simplex infection (orolabial, genital or anorectal of
more than one month’s duration or visceral at any site) 
• Oesophageal candidiasis (or candidiasis of trachea, bronchi or lungs) 
• Extrapulmonary tuberculosis 
• Kaposi sarcoma 
• Cytomegalovirus infection (retinitis or infection of other organs) 
• Central nervous system toxoplasmosis 
• HIV encephalopathy 
• Extrapulmonary cryptococcosis including meningitis 
• Disseminated non-tuberculous mycobacteria infection 
• Progressive multifocal leukoencephalopathy 
• Chronic cryptosporidiosis 
• Chronic isosporiasis 
• Disseminated mycosis (extrapulmonary histoplasmosis, 
coccidiomycosis) 
 
 
 
 
• Recurrent septicaemia (including non-typhoidal Salmonella) 
• Lymphoma (cerebral or B cell non-Hodgkin) 
• Invasive cervical carcinoma 
• Atypical disseminated leishmaniasis 
• Symptomatic HIV-associated nephropathy or HIV-associated 
cardiomyopathy 
Footnotes: 
• *Unexplained refers to where the condition is not explained by other 
conditions. 
• ** Assessment of body weight among pregnant woman needs to 
consider the expected weight gain of pregnancy. 
 
 
Anti retroviral therapy: 
 In the initial years, HIV infection and AIDS was treated with 
Zidovudine.  After the discovery of protease inhibitors, 
combination therapy against HIV infection initiated with One 
Nucleoside Reverse Transcriptase Inhibitor, One Non-Nucleoside 
Reverse Transcriptase Inhibitor.  This various combination of 
antiretroviral drugs regimen is called as Highly Active Anti 
Retroviral Therapy (HAART). 
 A neurologically active anti retroviral drugs are; Nevirapine, 
Efavirenz, Stavudine, Zidovudine, Lamivudine, Abacavir and 
Indinacir.  Principles for selecting  the first line regimen in HIV 
infection (NACO guideline) 
i) Choose one NRTI -  Stavudine (or) Zidovudine 
ii) Choose one NNRTI ( Nevirapine (or) Efavirenz) 
iii) Choose Lamivudine in all regimens. 
 In our ART centre in Tirunelveli Medical College Hospital, 
commonly used first line ART regimen are  
• SLN - Stavudine, Lamivudine and Nevirapine 
• ZLN – Zidovudine, Lamivudine and Nevirapine 
• SLE – Stavudine, Lamivudine and Efavirenz 
• ZLE – Zidovudine, Lamivudine and Efavirez 
If CD4 count is not increasing with first line regimen (or)  
decreasing from previous level, then plasma viral load estimation 
with be carried out and  second line regimen will be started. 
Zidovudine: 
 Zidovudine was the first anti retroviral drug approved for 
the treatment of HIV infection and belongs to the group of drug 
called Nucleoside Reverse Transaiptase Inhibitors (NRTIs).  The 
currently recommended dose of AZT is 300 – 600mg per day.  
Main side effects seen with AZT are anemia, leucopenia, ulcers in 
lips, mouth and tongue, bone marrow depression, loss of appetite,  
myalgias, bleeding tendency. 
Stavudine (d4T): 
 Stavudine belongs to the group of drug NRTI.  Commonly 
used as 100mg daily, in adults more than 60kg weight.  Common 
side effects noted are peripheral neuropathy, pancreatitis and 
lipoatrophy. 
Lamivudine: 
 One of the commonly used (3TC) NRTI group drug in ART.  
Dose used is 150mg twice daily (or) 300mg once daily.  Side effects 
are rare when  compared to Zidovudine and Stavudine. 
 Nevirapine (NVP): 
 Belongs to the group of drug called Non Nucleoside Reverse 
Transcriptase Inhibitors (NNRTI).  Started with 200mg daily for 2 
weeks followed by 400mg once  daily.  Side effects noted are skin 
rash, hepatitis and severe life threatening hepato toxicity observed 
when used with initial CD4 count >250 cells / mm3 in women and  
>400 cells / mm3 in men. 
Efavirenz (EFV):  
 Another drug of NNRTI group commonly used in ART.  
Dosage is 600mg once daily.  Efavirenz to be taken on empty 
stomach and avoid taking after high fat meals because of inceased 
peak concentration.  Side effects noted are dizziness, somnolence, 
insomnia, abnormal dreams and teratogenicity. 
 After the introduction of HAART  in HIV infection, various 
studies analyzed the effectiveness of HAART in the 
Neuropsychological impairment in HIV patients in all over the 
world. 
 Sacktor et al in 1998 studied the effect of HAART in the 
neuropsychological impairment due to HIV infection.  Study 
group comprised of 474 homosexuals and followed for two years 
from 1995 to 1997 after administration of HAART.  Results 
revealed that HAART participants showed better performance 
over the one year period of treatment in psychomotor speed and 
speed of information processing in Trail making Test B, when 
compared to antiretroviral naïve patients. 
 Tozzi et al in 2004 studied 70 patients on HAART and study 
results revealed that neuropsychological impairment  in patients 
receiving HAART was associated with reduced Health Related 
Quality of life (HRQOL). 
 Lucette et al in (2004) did a study on 97 HIV positive 
patients and 41 patients were studied on Neuro active HAART 
with better Blood Brain Barrier (BBB)  penetration and 56 patients 
with HAART.  The results showed that both groups did not  differ 
from one another on neuropsychological performance and the 
neuro HAART group showed significantly better memory 
performance its on the HAART group. 
Neuropsychological assessment in HIV infected 
populations: 
 In 1989, National  Institute of Mental Health NIMH 
conducted workshop on "Neuropsychological Assessment 
Approaches", neuropsychological test batteries should directly 
assess the areas of function that are deficient.  Test batteries 
measures processes in the following seven cognitive domains, 
attention, verbal and visual memory, information processing 
speed, abstraction and executive functioning, language, 
visuospatial, and visuo constructive and motor. 
 While the existing literature reveals several various test 
measures are commonly used and widely accepted in the 
assessment of neuropsychological impairment due to HIV-1 
infection, there is not a single specific battery (or) empirically 
validated "gold standard".  Traditional batteries such a certain 
measures from Halstead – Reitan Battery, measures assessing 
memory, and the Wechsler Adult Intelligence Scales appear to be 
the most frequently used (Gonzalez et al 2003).  The 
aforementioned 1989 NIMH workshop continues to be the guiding 
force in determining which measures to use to assess HIV related 
cognitive decline.  (Carey et al 2004; Gonzalez et al 2003). 
 For the assessment of premorbid intelligence WAIS-R 
vocabulary, National Adult Reading Test and Raven’s Standard 
progressive matrices are used.  
 For testing the attention / working memory domain, WAIS-
R, Digit spasm,  Digit Vigilance, Paced Auditory Serial Addition 
Test (PASAT), Trail Making Test-A, Antisaccadics Eye movements 
for 20 commands etc are used. 
 For assessing the domain of learning and memory, California 
verbal learning Test (CVLT), Reproduction  Test (WMS), Story 
learning, story memory delay free recall, figure learning, figure 
memory delay free recall,  recall of 4 words, etc are used in various 
batteries. 
 For assessing the speed of processing,  commonly available 
test batteries include WAIS-Digit symbol substitution test, Digit 
vigilance, Trail making test A, WAIS-III symbol search, Alphabet 
writing, simple and choice Reaction time (Go/NoGo), symbol 
search (WAIS-III). 
 Executive function domain is assessed by category test, trails 
test A & B, Winconsin card sorting test. 
 Language function is assessed by verbal fluency (phonemic 
and category), Boston Naming test, Thurstone word fluency, 
controlled Auditory word association test. 
 Visuoperception / visuomotor domain is assessed by WAIS-
R Block design,  Embedded figures test and Money’s Standardised 
road-map test of direction sense. 
 Constructional abilities are assessed by WAIS-R  Block 
design, Tactual performance test and copy a cube. 
 Fine motor abilities are assessed by Grooved peg board test 
and alphabet writing and gross motor abilities assessed by finger 
tapping and Grip strength. 
 For psychiatric assessment, following test batteries are used 
in various studies.  They includes Diagnostic Interview Schedule 
(DIS), Hamilton Reading Scale for Depression (HRSD),  
Spielberger  State-Tract Anxiety Immentary STAI, Mini mental 
State Examination, Beck Depression Inventory (BDI), Profile of 
Mood State (POMS), Structured Clinical Interview for DSM-IV and 
Composite International Diagnostic Interview (CIDI). 
 WHO Neuropsychological test batteries consists of Trail 
making test A, WHO/VCLA Auditory verbal learning, 
WHO/VCLA picture memory  Interference, WAIS Digit symbol, 
color trails I,  color Trails II, Verbal fluency (Names, animal), WAIS 
Block Design,  Grooved Peg board, Time Gait. 
 Gupta et al in NIMHANS, Bangaluru, used following test 
batteries for assessing the neuropsychological domains and were 
verbal-N-Back task,  WHO-AVLT, Visual N-Black Task, Tower of 
London, phonemic fluency, category fluency (Animal naming), 
Finger tapping. 
1. Digit Vigilance Test : DVT 
 The Digit vigilance test (Lezak, 1995) consists of numbers 1 
to 9 randomly ordered and placed in rows on a page. There are 30 
digits per row and 50 rows on the sheet.  The digits are closely 
packed on the sheet.  The same level of mental effort (or) attention 
deployment is required over a period of time.  The subject has to 
focus on the target digits like 6 and 9 amongst other distraction 
digits.  Inability to sustain and focus attention leads to both 
increased time to complete the test as well as errors.  Digit 
Vigilance Test tests sustained attention.  Frontoparietal network 
mediates sustained attention. 
2. Digit Symbol Substitution Test (DSST): 
 The digit symbol substitution test (Wechsler, 1981) is a test of 
visuo motor coordination, motor persistence, sustained attention 
and response speed.  Rapid information processing is required in 
order to substitute the symbols  accurately and quickly.  The test 
consists of a sheet in which numbers 1 to 9 are randomly arranged 
in 4 rows of 25 squares each.  The subject substitutes each number 
with a symbol using a number symbol key given on the top of the 
page.  The first ten squares are for practice. DSST is used to 
measure mental speed.  Mental speed is a  composite  measure,  
which requires rapid processing of  information and information 
processing speed requires coordination  of different  areas of the 
brain. 
3. Triads test: 
 The triads test was developed at NIMHANS, Bangaluru.  It 
combines a verbal triads task with a  tactual  number identification 
task.  The two tasks differ with reference to the stimulus modality 
and the nature of stimulus processing. The nature of the response 
is similar in that both the tasks require a verbal response.  
Therefore it is hypothesized that the attention resource pool 
tapped by the  two tasks are partially different.  This partial  
overlap within the attention resource pool in terms of the overlap 
of the nature of response demands division of  attention.  Triads  
test assesses divided attention and is closely  related to the central 
executive function of working memory. 
4. Animal Naming test: 
 The animal naming  test (Lezak, 1995) requires the subjects 
to generate names of animals for one minute.  Animal naming test 
tests the category fluency.  In category fluency, unlike in phonemic 
fluency, it is the content of  the words, rather that the phonetic 
similarly of the words, that is regulated.  Verbal fluency activates 
frontal lobes, particularly the prefrontal cortex in the  language 
dominant  hemisphere. 
5. Auditory Verbal Learning Test: 
 The Rey’s Auditory Verbal Learning Test (AVLT) (Schmidt, 
1996) adopted for different cultures by WHO (Maj et al, 1994) was 
adopted to suit conditions in India.  Rey originally developed the 
test in 1964.  It consists of words designating  familiar objects like 
vehicles,  tools, animals and body parts.  There are two lists A and 
B, with different words in each list.   
 Prefrontal cortices   are important  for the organization of the 
material,  verification of recalled material and  formulating 
heuristic strategies for learning.  Hippocampal structures  are 
important for association between events discrete in time and 
space. 
6. Trial Making Test (TMT) A: 
 Trial Making Test A consist of 25 circles distributed  over a 
sheet of paper.  A, the circles are numbered 1 – 25, and the patient  
should draw lines to connect the numbers in ascending order.  The 
patient  should be instructed to connect the circles as quickly as 
possible, without lifting the pen or pencil from the paper.  Time 
patient takes to   complete is calculated. If the patient makes an  
error,  point it out immediately and allow the  patient to correct it.  
Errors affect the patient’s score only in that the correction of errors 
is included in the completion time for the task. 
Trial making test A assesses information processing speed,  and 
executive function.                               
7. Standard Progressive Matrices: 
 Raven’s Standard Progressive Matrices (1936) are multiple 
choice tests of abstract reasoning which are, also used of 
assessment for intelligence.  It is originally developed by John 
C.Raven in 1936.    The booklets consists of  five sets (A to E) of 12 
items each  (eg. A1 through to A12),  with items within a set 
becoming increasingly difficult, requiring ever greater cognitive 
capacity to encode and analyse information.  All items are 
presented in black ink on a white  back ground.  In each test items, 
a patient is asked to identify the missing segment required to 
complete a larger pattern.  Many items are presented in the form of 
a 3 x 3 (or) 2 x 2 matrix, giving the test its name. 
 Adequate standardization, ease of use (without written (or) 
complex instructions), and minimal cost per person tested are the 
main reasons for its widespread international use in most 
countries of the world. 
 
  
  
  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
  
 
 
 
 
 
Materials & methods 
MATERIALS AND METHODS 
 
 The study on neuropsychological assessment of HIV patients 
on ART was approved by the Institute  Ethical Committee of 
Tirunelveli Medical College Hospital.  The study was carried out 
from the period of March 2011 to Feb 2012. 
Inclusion criteria: 
i) HIV positive patients  diagnosed by ELISA attending 
ART clinic in TVMCH.  
ii) Patients age between 16 years and 65 years. 
iii) Patient should be a literate (able to read and write and 
capable of doing neuropsychological tests). 
Exclusion criteria: 
ii) Patients with past (or) present neurological disorders (eg: 
TBM, CNS Toxoplasmosis,CVA etc) 
iii) Patients with past (or) present  psychiatric illness. 
iv) Patients with substance abuse and dependence. 
v) Patients with H/o head injury. 
vi) Patients with acute severe medical illness which could 
interfere with the comprehension and unable to perform 
the study. 
 
 
 
Methodology: 
 HIV positive patients attending ART centre is Tirunelveli 
Medical College Hospital were selected for this study.  HIV 
positive patients who were on ART were selected for study on the 
basis of inclusion and exclusion criteria.   The study population 
was explained about the purpose and nature of the study initially 
and informed consent was obtained from all patients. 
 Demographic profile of patients was collected.  Age, Sex, 
marital status, education status,  duration of HIV infection,  
duration of ART, ART regimen and clinical  stage of HIV infection 
were noted. 
 For all  selected patients,  baseline CD4, and recent CD4 
count were noted.  All routine biochemical blood  investigation 
like Blood Sugar, Urea, Creatinine,  Liver Function Tests,  complete 
hemogram,  Chest X-ray,  Ultrasound abdomen were done.   
CT Brain study was done in all selected patients. 
  A detailed history was taken from all patients with special 
focus on higher cognitive functions and lobar functions.  
Neurologic  examination was done in all patients.  Detailed  higher 
mental  functions and lobar functions examination was done.  
Cranial nerves examination, spino motor system,  extra pyramidal 
system,  sensory system,  cerebellum and autonomic nervous 
system were examined in detail. 
 Higher cognitive functions focusing on attention / working  
memory, sustained attention,  language,  learning and memory, 
visuo motor function,  executive functions, information processing 
speed,  and co ordination were examined in detail.  Regular higher 
mental functions and lobar function examination was 
supplemented  by neuropsychological  test batteries to quantity 
the deficits in various  domains. 
 The clinical  examination findings and neuropsychological  
test batteries findings were noted and results were obtained  with 
statistical analysis. 
Neuropsychological test batteries used are: 
1. Digit vigilance Test (Lezak, 1995) 
2. Digit symbol substitution test (Wechsler, 1981) 
3. Triads test (NIMHANS, NEUROPSYCHOLOGICAL 
BATTERY, 2004) 
4. Animal names test (Lezak, 1995) 
5. Auditory verbal learning test (Schmidt, 1996) 
6. Trial making test A. 
7. Standard progressive matrices (Raven, 1989) 
The domains studied include 
1. Attention 
2. Memory 
3. Language 
4. Cognition 
5. Frontal lobe functions 
6. Parietal lobe functions 
7. Temporal lobe functions 
8. Occipital lobe functions 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Results & Observation 
RESULTS AND OBSERVATION 
 
Data and study group: 
 Total number of patients enrolled in this cross-sectional 
study is 50.  Males were 26 (52%) and females were 24 (48%). 
Age group: 
 Study population was in various age groups.  Maximum age 
studied in this study was 59.  minimum age studied was 26. 
 Males were aged from 27 years to 59 years. 
 Females were aged from 26 years to 55 years.  Most common  
age group in our study population is from 36  - 45 years.  29 
patients were in 36 – 45 age group and forms 58% of this study.  
Next common age group noted is 26 – 35 years.  In this age group 
13 patients were present and forms 26% of study population. 
  
Age group Male  Female Total 
16 – 25  - - - 
26 – 35 4 (8%) 9 (18%) 13 (26%) 
36 – 45  17 (34%) 12 (24%) 29 (58%) 
46 - 55 4 (8%) 3 (6%) 7 (14%) 
56 - 65 1(2%) -  1 (2%) 
Total 26 (52%) 24 (48%) 50 (100%) 
  
 
 
 
 Education: 
 In this study, patients educations status ranged from 3 years 
of school education to college under graduates degree education. 
 Most of the patients had school education.  27 patients had   
6 – 10 years of school education.  21 patients had 3 – 5 years of 
school education.  One patient had 12 years of school education 
and another patient had completed BA degree. 
 
Years of education Male Female  Total 
3 – 5 yrs of school 10 11 21 
6 – 10yrs of school 14 13 27 
11 – 12 yrs of school 1 -  1 
College education 1 - 1 
Total 26 24 50 
 
Stage of HIV infection: 
 In this study, patients  were present in various stages of  
WHO  classification of HIV infection / AIDS by clinical case 
definition.   Most common  study population were noted in clinical 
stage III – 24  patients (48%), followed by clinical stage I.Seventeen 
patients were in clinical stage I (34%).   7 patients were in clinical 
stage II (14%) and two patients were in clinical stage IV (4%). 
 Of 26 male patients, 16 patients were in clinical stage III (i.e) 
61.5% of male population in stage III.  Of 24 female patients, 12 
patients were in clinical stage I (50%), followed by 8 patients were 
in stage II (16%). 
  
Stage Male Female Total 
I 5 12 17 
II 4 3 7 
III  16 8 24 
IV 1 1 2 
Total  26 24 50 
  
HIV infection duration: 
 Patients included  in study population had HIV infection 
duration ranging from 3 months to 10 years.  Of total 50 patients,  
19 patients  having HIV infection 37 – 48 months,  followed by 9 
patients having more than 5 years of HIV infection. 
 
HIV Duration Male Female Total  
< 2 years 7 3 10 
25 – 48 months 13 13 26 
> 48 months 6 8 14 
Total  26 24 50 
 
 
 
 
 
ART Duration: 
 Similarly, the study population also had  varying duration of 
ART regimen in the treatment of HIV infection.   ART duration 
ranged from 2 months to 6 years. 
 
HAART Duration Male Female Total  
1 – 12 months 7 4 11 
13 – 24 months 3 2 5 
25 – 36 months 6 3 9 
37 – 48 months 6 12 18 
49 – 60 months 2 1 3 
> 60 months 2 2 4 
Total  26 24 50 
 
ART Regimen: 
 The study population was treated with three drugs regimen 
of ART, most commonly used ART regimen in this study is ZLN 
(Zidovudine, Lamivudine and Nevirapine)  (i.e) 25 patients (50%) 
were on ZLN regimen,  followed by SLN (Stavudine,  Lamivudine, 
Nevirapine) regimen with 11 patients (22%). 
 
 
 
 
 
 
ART Regimen Male  Female  Total  
ZLN 15 10 25 
SLN 4 7 11 
SLE 3 1 4 
ZLE 1 1 2 
ZLN → ZLE - 1 1 
SLN → ZLN - 1 1 
SLE → ZLN 1 2 3 
SLE → SLN 1 1 2 
ZLE → ZLN 1 0 1 
Total  26 24 50 
 
Baseline CD4: 
 Baseline CD4 counts of  study population were noted.  It 
ranged from 34 to 649.  
 
Baseline CD4 Male Female Total 
< 200 19 16 35 
201 - 400 6 7 13 
401 – 600 1 - 1 
601 – 800 - 1 1 
> 800 - - - 
Total 26 24 50 
 
70% (35 patients)  had baseline CD4 counts less than 200 followed 
by 26% (13 patients) had baseline CD4 between 201 – 400. 
Recent CD4: 
 Similarly,  recent CD4 count of study population noted.   It 
ranged from  73 to 950.  38% (19 patients) had CD4 count between 
201 – 400 followed by 34% (17 patients) had CD4 count less than 
200.  
 
Recent CD4 Male  Female Total 
< 200 15 2 17 
201 - 400 8 11 19 
401 – 600 2 3 5 
601 – 800 - 7 7 
> 800 1 1 2 
Total 26 24 50 
 
Higher cognitive function examination results: 
 Clinical neuropsychological examination of study 
population revealed deficits in various domains of cognitive  
functions. 
 Attention tested by digit forward,  digit backward,  Go-No-
Go test, spell backward and vigilance revealed deficits in 31 
patients (62%). 
 
 
 
 
 
Attention : 
ART duration Impaired Normal 
< 2 year 12 4 
> 2 year 19 15 
Chi square 2.54 
P value 0.11 
CD4 count Impaired Normal  
< 200 10 7 
> 200 21 12 
Chi square 0.0005 
P value 0.9805 
 Immediate memory testing revealed deficits in 28 patients, 
(56%) of study population.  Immediate memory is tested by Digit 
repetition (DF & DB). 
Immediate memory: 
ART duration Impaired Normal 
< 2 year 7 9 
> 2 year 21 13 
Chi square 0.779 
P value  - 0.377 
CD4 count Impaired Normal  
< 200 7 10 
> 200 21 12 
Chi square 1.446 
P value  - 0.229 
 Recent  memory evaluation done by delayed recall of words 
revealed deficits in 16 patients (32%) of this study group. 
Recent memory: 
ART duration Impaired Normal 
< 2 year 9 7 
> 2 year 7  27 
Chi square 7.94  
P value  0.004* Statistically significant  
CD4 count Impaired Normal  
< 200 6 11 
> 200 10 23 
Chi square 0.451 
P value   0.501 
 Calculation difficulty was noted in 13 patients (26%) of study 
population. 
Calculation: 
ART duration Impaired Normal 
< 2 year 4 12 
> 2 year 9  25 
Chi square 0.054 
P value   0.816 
CD4 count Impaired Normal  
< 200 4 13 
> 200 9  24 
Chi square 0.0029 
P value  0.9570 
 Category fluency was impaired in 6 patients (12%) of study 
population.  Category fluency tested by animal naming test in one 
minute. 
Fluency: 
ART duration Impaired Normal 
< 2 year 3 13 
> 2 year 3  31 
Chi square 2.129 
P value  0.144 
CD4 count Impaired Normal  
< 200 1 16 
> 200 5  28 
Chi square 0.241 
P value  0.623 
 Constructional ability was impaired in 11 patients (22%). 
Constructional ability: 
ART duration Impaired Normal 
< 2 year 4 12 
> 2 year 7  27 
Chi square 0.504 
P value   0.477 
CD4 count Impaired Normal  
< 200 4 13 
> 200 7  26 
Chi square 0.294 
P value  0.587 
 Peripheral neuropathy is observed  in 16 patients (32%).  8 
patients  each with peripheral neuropathy had taken ART less than 
2 years group and more than 2 years of ART.  
Peripheral neuropathy: 
ART duration  Impaired Normal 
< 2 year 6 10 
> 2 year 10 24 
Chi square 0.79 
P value  0.37 
CD4 count Impaired Normal  
< 200 5 12 
> 200 11  22 
Chi square 0.001 
P value  0.969 
Neuropsychological test results: 
 To supplement higher cognitive clinical examination and to  
quantify the  neuropsychological  impairments,neuropsychological 
test batteries were used after clinical examination. 
Digit Vigilance test: 
 This test is used for testing sustained  attention,  visuo motor 
coordination  and processing speed.  30 patients had deficits in 
doing DVT (60% of study group). 
 
 
 
 
 DVT: 
ART duration Impaired Normal 
< 2 year 9 8  
> 2 year 21 12 
Chi square 0.178 
P value   0.672 
CD4 count Impaired Normal  
< 200 10 7  
> 200 20 13 
Chi square 0.032 
P value  0.85638 
Digit Symbol Substitution Test:  
 It is a test of motor persistence, response speed,  visuo motor 
coordination and sustained attention.  33 patients had deficits in 
Digit Symbol Substitution Test (66%). 
DSST: 
ART duration Impaired Normal 
< 2 year 14 4 
> 2 year 19 13 
Chi square 2.60  
P value   0.10 
CD4 count Impaired Normal  
< 200 10 7  
> 200 23 10 
Chi square 0.201 
P value  0.653 
Triad test is used to assess the divided  attention.  23 patients were 
found to have deficit while doing triads test (46%). 
Triads test: 
ART duration Impaired Normal 
< 2 year 10 6  
> 2 year 13 21 
Chi square 3.57  
P value  0.05*  Statistically significant  
CD4 count Impaired Normal  
< 200 6 11 
> 200 17 16 
Chi square 0.61  
P value   0.43 
Auditory Verbal Learning Test: 
 Auditory Verbal Learning Test is used to  assess  learning 
and memory.  27 patients had deficit in AVLT testing (54%). 
AVLT: 
ART duration Impaired Normal 
< 2 year 13 3 
> 2 year 14 20 
Chi square 8.564 
P value  0.003* Statistically significant  
CD4 count Impaired Normal  
< 200 11 6  
> 200 16 17 
Chi square 1.892 
P value  0.169 
Trial Making Test: 
 Trial Making Test A is used to assess the executive function 
and speed of information processing.  16 patients  found to have 
deficit in Trial Making Test A (32%). 
TMT-A 
ART duration Impaired Normal 
< 2 year 8 8 
> 2 year 8 26 
Chi square 4.729 
P value  0.029* 
CD4 count Impaired Normal  
< 200 5 12 
> 200 11 22 
Chi square 0.001 
P value   0.969 
Animal Naming Test : 
ART duration Impaired Normal 
< 2 year 4 12 
> 2 year 2 32 
Chi square 5.677 
P value  0.017* 
CD4 count Impaired Normal  
< 200 4 13 
> 200 2 31 
Chi square 5.005 
P value  0.025* Statistically significant  
Raven’s Standard Progressive Matrices: 
Raven’s Standard Progressive Matrices test is used for 
assessing the abstract reasoning.  19 patients found have 
impairment.  
  
ART duration Impaired Normal 
< 2 year 11 5 
> 2 year 8 26 
Chi square 11.231 
P value  0.0008* Statistically significant  
CD4 count Impaired Normal  
< 200 6 11 
> 200 13 20 
Chi square 0.00039 
P value  0.980  
Analysis of  study group: 
 In this study,  detailed clinical exam of higher cognitive  
functions and lobar functions,  cranial nerves,  spino  motor 
system,  sensory system,  cerebellar system,  extra pyramidal 
system,  autonomic  nervous system were carried out, which was 
supplemented by the neuropsychological test batteries to quantify  
the  deficits in various domains. 
 In this study group among the total 50 number of patients, 
26 (52%) were males and 24 (48%) were females. 
 Patients with various age group were included in our study 
ranging from 26 years to  59 years.  Males were aged  from 27 
years to 59 years and females aged from 26 years to 55 years.  58% 
of study population from 36 – 45 years age group (29 patients) 
followed by 26% from age group of 26 – 35 years (13 patients). 
 Mean age of this study population is 39.26 (SD 7.108).The 
study population were in various stages of HIV infection ranging 
from stage I to stage IV.  Most common  WHO clinical  stage noted 
in our study is stage III (48%) followed by stage I (34%).  14% with 
stage II infection and 4% had stage IV disease. More number of 
male patients (17 patients) were in  advanced stages (III & IV) than 
female patients (9 patients),  in this study. 
 The duration of HIV infection ranged from 3 months to 10 
years.  Most of this patients had more than 2 years of HIV infection 
(40 patients). 
 In this study  patients were on ART with varying duration.  
16 patients (32%) had  taken  ART less than two years.  34 patients 
(68%) were on ART more than two years. 
 Most common ART regimen taken by study population is 
ZLN (Zidovudine), Lamivudine and Nevirapine) 25 patients (50%) 
followed by SLN (Stavudine,  Lamivudine and Nevirapine) 11 
patients (22%).  
 Baseline  CD4 of this study population ranged from 34 to 
649 with a  mean of 175.30 (SD 116.989).   70% of study population 
had CD4 count less than 200  (35 patients).   26% patients had CD4 
count between 201 – 400 (13 patients). 2% (1 patient) had CD4 
count between 401 – 600 and 2% (1 patient)  had baseline CD4 
count between 601 – 800. 
 Recent CD4 count ranged from 73 to 950 with mean CD4 
count of 331.32, (SD 222.791).  34 % (17 patients) had CD4 count 
less than 200.  66 % (33 patients) had CD4 count more than 200. 
38% (19 patients) were with CD4 count 201 – 400. 10% (5 patients) 
were with CD4 count 401 – 600. 14% (7 patients) were with CD4 
count 601 – 800. 4 % (2 patients) were with CD4 count more than 
800.       
Analysis of Neuropsychological  impairment in study 
population: 
 The detailed  clinical  higher cognitive  functions and lobar  
function examination done in study population revealed the 
deficits in various domains. 
 The most commonly affected higher  cognitive function is 
attention.  31 patients  were affected by attention deficits and they 
were able to say digit forward < 5 numbers.  Digit backward  
performed also revealed deficits in 31 patients. 
 Immediate memory is affected in 28 patients of study and  
recent memory affected in 16 patients. 
 Difficulty in calculation is noted in 13 patients  and unable to 
proceed 2 – 3 steps of serial subtraction. 
 Similarly 11 patients  in study group had difficulty in 
constructional ability. 
 16 patients  in the study population had peripheral 
neuropathy. 
 The neuropsychological  test batteries  used in this study 
subsequent  to detailed clinical  neuropsychological examination.  
The following deficits  are noted in various  test batteries  
employed  in the study. 
 In Digit Vigilance Test  30 patients (60%) had deficits in 
attention and response speed. 
 In Digit Symbol Substitution  Test 33 patients (66%) had 
deficits in the motor persistence,  sustained attention,  visuo motor 
coordination. 
 In Triad Tests 23 patients (46%) had deficits in divided 
attention. 
 In Auditory Verbal Learning Test, 27 patients (54%) had 
deficits in learning and memory. 
 In Animal Naming Test 6 patients (12%) had deficits in 
category fluency. 
 In Trial Making Test A, 16 patients (32%) had deficits in 
executive  functions and speed of information processing. 
 In Raven’s Standard Progressive Matrices, 19 patients (38%) 
had deficits in abstract reasoning.   
 
Neuropsychological 
domains 
Affected % 
Attention 31 
 
62 
 
Memory 
 
28 
 
56 
 
Language 
 
11 22 
 
 Cognition  Affected % 
a)Fund of knowledge 
b)Judgement  
c)Calculation 
d)Abstract thinking 
5 
3 
11 
19 
10 
6 
22 
38 
 
In this study  population,  31 patients had  deficits in 
attention.  Most common neuropsychological  domain affected is 
attention (62%) followed by memory (56%). 
 In memory, the immediate memory was affected in 28 
patients and recent  memory was impaired in 16 patients.  Both 
immediate  memory and recent memory were  impaired in 11 
patients. 
 In language  domain tested, all patients  were able to 
comprehend,  responded  appropriately, able to read and write.  
Repetition were normal in all patients.  6 patients had impairment 
in category fluency.  11 patients  had impairment in copying. 
 Cognition was assessed by fund of knowledge,  new learning 
abilities,   judgements, calculation and abstract thinking.  5 patients 
had  poor fund of knowledge,  3 patients had impaired  
judgements,  11 patients had calculation difficulties and 19 patients 
found to have deficit in abstract thinking. 
 Frontal lobar function were  affected in most of the  patients 
in this study.  Motor persistence and response speed was impaired 
in 33 patients  as tested by Digit  Symbol Substitution Test.  
Executive function and speed of information processing was 
impaired in 16 patients.  Divided attention was tested by Triads 
test and found to be impaired in 23 patients.  
Frontal lobar functions Affected % 
Motor persistence and response speed 
Executive function 
Divided attention 
33 
16 
23 
66 
32 
46 
  
Parietal lobar functions examination of patients revealed 
deficit in calculation and constructional ability.  Calculation 
impairment noted in 13 patients  (26%) and constructional ability 
was impaired in 11 patients (22%). 
Parietal lobe 
function  
Affected % 
Calculation 
Constructional 
ability 
13 
11 
26 
22 
 
Temporal lobe examination revealed  deficits in verbal memory 28 
patients 56% behavioral changes were noted in 10 patients like 
depression. 
Temporal lobe 
function 
Affected % 
Verbal memory 
Behavioral changes 
28 
10 
56% 
20% 
 
Examination of occipital lobe  functions in study population 
found to be normal in all patients. 
In this study only 6 patients were found to be normal in both 
clinical examination of higher cognitive functions and lobar 
functions.  The duration of HIV infection in this 6 patients   ranged 
from 21 month to 72 months.  3 patients were in stage III, 2 
patients were in stage II, and one patient had stage I infection. 
Duration of HIV infection  in neuropsychological 
affected population 
Attention: 
HIV Duration Affected  Total  % 
<24 months 5 10 50% 
25 – 48 months 17 26 65.3% 
>48 months 9 14 64.2% 
Total  31 50 62% 
 
Memory (Immediate) 
HIV Duration Affected  Total  % 
<24 months 5 10 50% 
25 – 48 months 16 26 61.5% 
>48 months 7 14 50% 
Total  28 50 56% 
 
Calculation 
HIV Duration Affected  Total  % 
<24 months 3 10 30% 
25 – 48 months 6 26 23% 
>48 months 4 14 28.5% 
Total 13 50 26% 
 Constructional ability 
HIV duration Affected  Total  % 
<24 months 3 10 30% 
25 – 48 months 4 26 15.3% 
>48 months 4 14 28.5% 
Total 11 50 22% 
 
Recent memory: 
HIV Duration Affected  Total  % 
<24 months 6 10 60% 
25 – 48 months 5 26 19.2% 
>48 months 5 14 20.8% 
Total 16 50 32% 
 
Peripheral Neuropathy: 
HIV Duration Present  Absent  % 
<24 months 3 10 30% 
25 – 48 months 9 26 35% 
>48 months 4 14 28.5% 
Total 16 50 32% 
 
 
 
 
 
Tests: 
1. DVT: 
HIV duration Impaired  Total  % 
<24months 7 10 70% 
25 – 48 months 17 26 65.3% 
>48 months 9 14 64.2% 
Total 33 50 66% 
 
2. DSST: 
HIV Duration Impaired Total  % 
<24 months 7 10 70% 
25 – 48 months 17 26 65.3% 
>48 months 9 14 64.2% 
Total 33 50 66% 
 
3. Triads test: 
HIV Duration Impaired Total  % 
<24months 7 10 70% 
25 – 48 months 11 26 42.3% 
>48 months 5 14 35.7% 
Total 23 50 46% 
 
 
 
 
 
4. AVLT 
HIV Duration Impaired Total  % 
<24 months 8 10 80% 
25 – 48 months 10 26 38.4% 
>48 months 9 14 64.2% 
Total 27 50 54% 
 
    5. TMT-A 
HIV Duration Impaired Total  % 
<24 months 4 10 40% 
25 – 48 months 7 26 26.9% 
>48 months 6 14 42.8% 
Total 17 50 34% 
 
6. Animal Naming Test: 
HIV Duration Impaired Total  % 
<24 months 2 10 20% 
25 – 48 months 2 26 7.6% 
>48 months 2 14 14.2% 
Total 6 50 12% 
 
7. Raven’s Standard Progressive Matrices: 
HIV Duration Impaired Total  % 
<24 months 7 10 17% 
25 – 48 months 6 26 23.07% 
>48 months 6 14 42.85% 
Total 19 50 38% 
  
 
  
Study 
group 
HIV duration ART 
Regimen 
 CD 4 count  
<24 
months 
25-48 
Months 
>48 
months 
ZLN  SLN <200  >200 
 
Normal 1 4 1 2 1 4 2 
One 
domain 
affected 
1 9 2 7 2 3 9 
Two 
domain 
affected 
3 5 2 3 2 4 6 
>Two 
domain 
affected 
5 8 9 14 6 6 16 
 
As the duration of HIV infection increases the number of   
domains affected as tested by clinical neuropsychological 
examination increases. 
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Discussion 
DISCUSSION 
 
In HIV/AIDS patients, neuropsychological  impairments  
have  been  well  documented  in all stages  of  infection  with  
varying  severities.  Prior  to  the antiretroviral  therapy  era, HIV 
associated  neuropsychological  disorders  manifested  as  HIV  
associated  dementia in  about  15 %  of   HIV positive  individuals.  
After  advent  of  Highly  Active  Anti Retroviral Therapy 
(HAART),  the incidence and prevalence of HIV associated 
dementia decreased, but milder  forms  of neuropsychological 
impairments are seen  in one or more domains. 
          Various studies  quote that   upto 50% of HIV -1 infected  
individuals will develop some form of HAND regardless of access 
to currently available ART.(Ellis R.et al-2007,Harezlak J  et al-
2011;Simioni S et -2010).   Under ART,  HAND has became  
milder,its course more protracted and  variable  in  symptoms.  It 
now overlaps with aging process and also with  other  
neurodegenerative  diseases  in HIV/AIDS  patients.  The  etiology  
of  persistent  neuropsychological  deficits in HIV/AIDS  patients 
on  HAART  remains  unclear. 
 The first  objective of this study is to determine prevalence of 
Neuropsychological  impairment in HIV patients on ART. 
 In this study,  the prevalence of neuropsychological 
impairment  observed in HIV positive  patients on ART is 88%. 
 The prevalence of neuropsychological impairments noted in 
various studies with varying ranges from 45 % to 86%. 
 Heaton RK et al in 1995 found that 86% of persons in 
HIV/AIDS  had neuropsychological deficits. 
 Grant I et al in 1987 in their study found that 55% of HIV 
infected patients in various stages had neuropsychological deficits. 
 Gupta et al in 2007 in South India, Bangaluru compared 119 
adults infected with HIV-1 sub type C who were not on  ART with 
normative data derived from an Indian sample of 540 healthy 
volunteers  with a  matched cohart of 126 healthy HIV-1 sero 
negative  individuals  and found a  high rate of (60.5%) mild to 
moderate  cognitive  deficits in the HIV positive patients, but no 
evidence of true dementia. 
 More recent studies conducted in HIV patients on HAART 
estimate that prevalence of neuropsychological  dysfunction 
(based on neuropsychological test batteries assessments) in HIV 
populations. Over all 45% of cohart had neuropsychological 
impairment based on a global neuropsychological rating in the 
CHARTER study group (Heaten et al 2009). 
 Yepthomi et al in 2006 collected data in a sample of 30 
treatment naïve HIV positive patients with median CD4 cell count 
of 97 and  compared with age and  education matched health 
controls from same region of Chennai in India showed significant 
differences in most of neuropsychological functions,  with lower 
performances obtained by the HIV positive individuals and noted 
neuropsychological difficulties were present  among individuals 
with sub type C virus in India with as many as 56% of the patients. 
 
 
 Comparison of prevalence with other studies 
Study Prevalence  in % 
In this study (2011 – 12) 
RK  Heaten et al (1995) 
Grant I et al (1987) 
Gupta et al (2007) 
CHARTER Group (2009 
Yepthomi et al (2006) 
88% 
86% 
55% 
60.5% 
45% 
56% 
 
The  prevalence noted in our study is  high when compared 
with other studies except Heaten et al (1995).  This may be due to 
detailed clinical neuropsychological  examination followed by 
neuropsychological test batteries examination done in this study.  
Most of other studies were done with  neuropsychological test 
batteries  alone. 
 The second objective of this study is to study the pattern of 
neuropsychological  impairment  in HIV patients on ART. 
 The following domains of neuropsychological functions 
were affected with varying percentages. 
1. Attention deficit noted in 62% 
2. Sustained attention deficit noted in 60% 
3. Divided  attention deficit noted in 46% 
4. Motor persistence, Response speed,  visuomotor 
coordination deficit noted in 66% 
5. Memory deficit noted in 56% 
6. Verbal learning and memory  impaired in 54% 
7. Abstract thinking and reasoning impaired in 38% 
8.  Executive function  impaired  in 34% 
9. Calculation difficulties noted in 26% 
10. Constructional ability impaired in 22%  
11. Animal naming test impaired in 12% 
 The pattern of neuropsychological  impairment noted in  
study conducted by Stephen Ferrando et al in 1998 on HAART  
taking HIVpatients  and not taking HAART  HIV positive patients  
revealed  following pattern of neuropsychological functions. 
 Verbal learning and memory is impaired in 50% of HAART  
taking patients  and DSST test found impairment in 45% of  
(assessing  motor persistence, response speed and sustained  
attention) HAART taking patients. 
 RK Heaten et al study on  the impact of HIV associated  
neuropsychological impairment on  every day functioning of(2004)  
HIV+ve  patient on ART revealed that deficits among  
neuropsychologically  impaired individuals were in domains of  
learning (68%), abstraction/executive functioning (54%), attention  
/working memory (53%), and motor functioning  (47%), are noted.  
Least prevalent  deficits were speed of information processing   
(36%), verbal learning (27%) and delayed  recall (25%) 
 Another study  evaluating the pattern of  neuropsychological  
performance in a  sample of HIV positive  patients  and HIV  
negative control subjects in Uganda revealed significant  group  
differences  on measures of verbal learning and memory, speed of  
processing,  attention and executive  function.  This study was  
done by Robertson et al in Uganda in 2007. 
 Similarly study done by Gupta et al in India in 2007 revealed  
60.5% of mild to moderate cognitive deficits and deficits  noted  
were in attention working memory, learning and  memory and   
fluency. 
 HIV enter the central nervous system early during the course  
of infection and cells infected by the HIV in CNS are blood derived  
macrophages, microglia, and astrocytes.  The neurons are not  
directly infected with HIV.  The neuronal damage occurs in HIV  
infection due to shed viral proteins such as gp 120 and Tat or  
indirectly neurotoxic molecules released by astrocytes  
macrophages and microglia.   
 Neuro imaging of HIV patients with neuropsychological  
impairments revealed white matter abnormalities in subcortical  
regions.  Fronto striatal loops in the sub cortical areas commonly in  
HIV patients involving fronto temporal and fronto parietal circuits  
leading to deficits commonly observed in attention, executive  
functions, speed of information processing, memory, language,  
calculation, and constructional ability. 
 Third objective of this study is to find out factors that may  
contribute to neuropsychological impairment in HIV positive  
patients in ART.  
 Neuropsychological impairment is seen in all stages of HIV  
infection from stage IV to stage I. 
Stage IV 
 Two patients were seen in stage IV  HIV infection in this  
study. One patients show decline in one domain another patients  
had two domains of neuropsychological functions.  Both of them  
having illness more than 3 years and both showed initial CD4  
count less than 200.  Multiple domains involvement is not seen in  
either of them because , their recent CD4 count showed good  
improvement when compared to baseline CD4 count.          
Stage III 
  Most of the patients in this study were in   WHO clinical 
stage III (24 patients).  In stage III  4 patients  showed deficit in one 
domain of neuropsychological  function. After  analysis  of these 
patients, we come to conclusion that even if CD4 count was less 
than 200 and even if duration of  HIV infection  varies from less 
than 2 years to more than 4 years, if the patient is exposed to ART 
very earlier, the neuropsychological impairment is less.  All  
patients  showed    good   response to ART as evidenced  by 
increase in CD4 recent count and all were more than  300. 
            7 patients showed deficit in two domains of 
neuropsychological function in stage III.  Analysis of this group 
revealed no good response to ART in term of increase in CD4 
recent count. In all these patients recent CD4 count is less than 300.  
We hypothesise that this may be due to initial high viral load 
which directly affect  neuropsychological functions of the brain. 
Duration of ART is less than one year in three patients. Five 
patients  had not shown marked increase in CD4 count.  Basal CD4 
count in  five patients were less than 200. Of which three patients 
had basal CD4 count less than 100. Thus initial very low CD4 
count may also contribute to neuropsychological decline. 
        In patients with more than two domains involvement in stage 
III, analysis of results revealed that most of the patients (9 out of 10 
patients) had initial CD4 count less than 200 and six of them had 
CD4 count less than 100. Even after the institution of ART for 
prolonged periods, only two patients showed improvement of 
more than 300 in recent CD4 count. Most of the patients were 
infected for more than 4 years  duration.  Even though many of 
them are on ART during this period, since their initial CD4 count 
were lower and even after adequate duration of ART, CD4 did not 
increase more than 300, we presume that initial viral load could 
have been more and would have caused CNS infection directly 
very early in the infection itself, which was smoldering.ART has 
exerted its beneficial role in such a way that even though multiple 
domains involvement is made out in this study, frank dementia is 
not made out in any of the patients, even though they were all  
clinically in stage III  and many of them were infected for the 
previous four years.      
Stage II 
          In stage II , two patients did not show any cognitive decline. 
Both patients showed initial CD4 count more than 200, and  they 
required ART only after 24 to 48 months of initial infection. It is 
presumed that initial viral load was less and CNS was not affected 
right from the beginning. Though their CD4 count declined 
recently which may be due to recent increase in viral load, the 
neuropsychological changes may take more time to manifest 
outside. 
       In stage II, two patients showed decline in one domain. Both 
patients were taking ART right from the beginning and initial CD4 
counts were more than 100, even though   less than 200.CD4 count 
improvement  was not more than 300. 
      In  stage II , two patients showed decline in two domains. Both 
patients were exposed to ART from the beginning and initial CD4 
counts were less than 200 and there was no adequate improvement 
in their CD4 count indicating more viral load especially in one 
patient in whom  even after 72 months of ART, CD4 count 
declined from 198 to 119. 
Stage I  
         Many of patients in stage I showed multiple domain 
involvement. Of total 17 patients in stage I, 10 patients had multi 
domain involvement. Their initial CD4 count was less than 250 in 
most of them(8 out of 10) and they showed good response to ART 
in term of increase in CD4 count(6 out of 10). But except two 
patients, all other patients were suffering from HIV infection for 
more than 3 years, some of them having HIV infection from 6 to 10 
years.  This long duration of HIV infection and initial low CD4 
count would indicate that 
          1.Iinitial viral load could have been more and CNS was 
infected early in the illness. 
         2. The continuous administration of ART has prevented the 
development of frank dementia even after 6 to 10 years of HIV 
infection, but the slow smoldering effect of HIV  has caused 
disturbances in the multiple domains of neuropsychological 
functions.  
 Analysis of study population on the basis of various stages 
of HIV infection from stage IV to stage I with respect to the 
severity of neuropsychological impairment (no of domains of 
involvement of neuropsychological functions) showed interesting 
facts with regards to the duration of illness, initial CD4 count, 
recent CD4 count and early or late initiation of ART.    
When analyzing patients  with two domains (10 patients)  
involvement  and more than two domain involvement (22 
patients),  persons having less than 200 in baseline CD4 were 23 
out of 32 patients.  Of these 23 patients,  10 patients initial base line 
CD4 count was less than 100.    
 Recently published  study of the CHARTER group on 1525 
HIV positive  participants revealed that the risk of 
neuropsychologic impairment (NPI) was lowest in patients whose 
CD4 cell count  was never allowed to fall to low levels before ART 
initiation, and suggested early initiation of ART as early as 
possible  might reduce the risk of developing HAND, the most 
common source of NPI among HIV infected individuals.  (Ronald 
J.Ellis et al – AIDS 2011).  Our study also showed 
neuropsychological decline in multiple domains in patients with 
baseline CD4 count less than 100. 
 In this study out of 32 patients who had two domains and 
more than two domain involvements, 21 patients  are on ART for 
more than 2 years of duration (9 patients  had taken ART 4 years 
(or) more than 4 years  in this 21 patients).  Only 12 patients out of 
these 32 patients had improvement in recent CD4  count to  more 
than 300. 
 So, despite ART for more than two years of duration, if there 
is no rise in CD4 count from the baseline, the chances of multi 
domain decline in cognitive function is more likely. 
 Late initiation of  ART was observed in 4 out of 32 patients 
who had two (or) more domains involvement  in the 
neuropsychological functions.   Early initiation of  ART might have 
helped to improve the  CD4 count there by improvement in 
neuropsychological functions.  A study conducted by  Mc Cutchan 
A et al in  2007 revealed that there was no association with CD4 
counts and neuropsychological impairment.  But this study did 
not include that factor of recent increase in CD4 count after ART.   
However the same study Mc Cutchan A et al in  2007,  
demonstrated an improved performance on neuropsychological 
tests over a  two year period from 3 to 5 years after initiating  
potent HIV treatment. 
 Long duration of HIV infection three (or)  more than 3 years 
is also associated  with neuropsychological impairment  as 
suggested by observation that out of 38 patients with two (or)  
more domains involvement,  24 patients had three years (or) more 
than 4 years of HIV infection. 
 From the above following inferences are made out. 
         Neuropsychological changes are seen in HIV infected patients 
from  stage I to stage IV. Absolute number of patients showing 
neuropsychological impairment in the multiple domains are 
dependent not only on clinical staging of HIV disease but also on 
various other parameters. From the results derived ,we 
understand that the initial CD4 count less than 200, and most 
importantly less than 100, poor response to CD4 count 
improvement even after adequate duration of regular ART intake 
failing to increase the CD4 count to more than 300 and duration of 
HIV infection more than 3 years and late initiation of ART are 
some of the factors that contribute to  disturbances in the 
neuropsychological functions. 
           Though a single variable may not indicate the  
presence or absence of neuropsychological disturbances and 
though a single variable may not indicate the  severity of 
neuropsychological dysfunction, presence of multiple factors as 
discussed above may be taken to represent the presence of  
neuropsychological dysfunction and or its severity.When multiple 
factors are present, neuropsychological dysfunction in multiple 
domains may be expected , though converse may not be true.
 Frank established dementia is not seen in study group on 
ART. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Conclusion 
CONCLUSION 
 
1. In this study,  88% of HIV patients on ART showed 
neuropsychological impairments.           
2. The pattern of neuropsychological impairments noted in this  
study population  include 
         A. Attention/ working memory is affected in 62%. 
         B. Executive function is affected in 32% . 
         C. Divided attention is affected in 46%. 
D. Parietal lobar functions are affected in 26%. (calculation &     
    constructional ability). 
  E. Temporal lobar functions are affected in 56%.(memory). 
3. Frank dementia is not observed in any of the patients 
studied. 
4. Initial CD4 count less than 100, poor response to CD4 count 
improvement even after adequate duration of regular ART 
intake failing to increase CD4 count to more than 300 and 
duration of HIV infection more than 3 years and late 
initiation of ART are some of the factors that  may contribute 
to disturbances in the neuropsychological functions.  
                  
 
 
 
 
 
  
 
 
 
Summary 
SUMMARY 
 
Neuropsychological impairments are observed in high 
percentage of HIV patients  on ART also,  causing impairments in 
attention/working memory, learning, executive functions, 
calculation and constructional ability. Initial very low CD4 count 
less than 100, long duration of HIV infection late initiation of ART 
and failure to improve CD4 count to more than 300 even after 
adequate duration of ART are some of the factors that may 
contribute to neuropsychological impairment in  HIV patients on 
ART. 
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Proforma 
PROFORMA 
 
Serial No  :      Date: 
Patient name : 
Age   : 
Sex   : Male / Female / Transgender 
Education  : 
Marital status :Single/Married/Separated/Divorced/widowed 
Occupation : 
Income  : 
Handedness : 
 
Medical and lab data: 
Known duration of HIV infection: 
Duration of ART  : 
ART Regimen       : 
WHO stage of HIV infection : I / II / III / IV 
Baseline CD4 count : 
Recent CD4 count : 
H/o head injury  : 
H/o psychiatric illness : 
H/o substance abuse : 
(or) dependence  
H/o comorbid  medical  
illness   : DM/HT/IHD/tuberculosis/syphilis 
  /Thyroid/Malignancy 
H/o radiation exposure / chemotherapy 
H/o exposure  to  heavy metals  
(Mercury/Lead/Bismuth/Arsenic)     
H/o drug intake Benzodiazepines/Barbiturates/Antidepressants/ 
Anticonvulsants/Narcotics 
H/o connective tissue disorder like rash/arthralgia/fever/ 
Photosensitivity/alopecia 
H/o exposures to commercial sex workers/Gay/ iv drug users 
H/o any neurological complaints 
If neurological complaints present 
It onset : Acute/subacute/chronic 
Course of illness : Static/progressive/fluctuating/ improves over 
time 
H/o memory loss (eg: frequent misplacing of objects, problem 
with money transaction, forgets what was read (or) heard) 
H/o difficulty in remembering relatives, personal and family 
events. 
H/o difficulty in learning (or) performing new tasks. 
H/o poor decision making, judgement, problem solving 
H/o any change in personality : Apathetic / Disinhibited 
H/o any mood change : sad/irritable/elated 
H/o any behavioral changes : Aggressive/out bursts of anger if 
provoked/sham rage/emotional lability (or) incontinence 
H/o difficulty in expression : word finding/naming/ 
comprehension/repeating/ reading/writing 
H/o difficulty in calculation:  
H/o getting lost in familiar areas (or) forgetting known routes 
H/o wandering tendencies 
H/o spatial disorientation within his home (or) office 
H/o difficulty in dressing/neglecting one half of the body while 
dressing (or) shaving 
H/o neglecting food on one half of the plate 
H/o excessive eating (or) craving for sweets 
H/o hypersexuality 
H/o loss of interest in sexual activities 
H/o sleep disturbance 
H/o delusion / illusion 
H/o hallucination : visual/auditory/olfactory/tactile/gustatory 
H/o hypermetamorphosias 
H/o difficulty in identifying familiar faces, objects and colours 
H/o difficulty in visual perception in one half of the field 
H/o cortical blindness (or) denial of blindness 
H/o alien limb phenomenon 
General examination of the patient: 
Conscious 
Oriented 
Anemia  
Cyanosis 
Clubbing 
Lymphadenopathy 
Glossitis 
Angular stomatitis 
Icterus 
Hyperpigmentation 
Photosensitivity 
Icthyosis 
Pulse 
BP 
Temp 
RR 
 
Examination of Higher mental function: 
I. General 
• Appearance 
• Handedness 
• Education 
• Insight 
• Cooperation 
• Mood/Emotions 
• Denial/Neglect 
• Level of consciousness 
II. Attention: 
• By observation 
• Digit Repetition 
a) Digit forward 
b) Digit backward 
• Vigilance 
a) Omission 
b) Commission 
c) Perseveration 
d) Go-on-go test 
e) Spell backward 
f) Serial subtraction 
Neuropsychological tests for attention 
1) Digit vigilance test 
2) Triads test 
III Language: 
1. Spontaneous speech 
a) Fluency 
b) Sentence length 
c) Articulation 
d) Paraphasias 
e) Grammar 
f) Prosody 
2. Verbal Fluency 
a) Words per minute 
b) Animal names per minute 
3. Comprehension 
a) Pointing commands 
b) Yes / No commands 
c) For written languages 
d) Gestural commands 
4. Repetition 
5. Naming 
a) Colours 
b) Objects 
c) Body parts 
d) Parts of objects 
6. Reading 
7. Writing 
a) To dictation 
b) To write body parts 
c) Write about his problems 
8. Spelling 
9. Copying 
a) Numbers 
b) Letters 
c) Gestures 
10. Music 
IV. Memory 
1. Immediate memory 
a) Orientation : Date/Day/Month/Year/Time to time 
b) Orientation 
In place :Floor/Place/Town/State/Country 
c) Self 
d) Doctor 
e) Attender 
f) DF 
g) DB 
h) Verbal repetition 
2. Recent memory 
a) Breakfast 
b) Recall 3 words 
c) Recall 3 words (improvement with clues) 
d) Paired associate learning 
3. Remote memory 
a) Personal events 
b) Family events 
c) Historical events 
V. Cognition: 
1. Fund of knowledge 
• Weeks in month 
• Days of a week 
• Months in a year 
• President 
• Father of nation 
• Prime minister 
• Chief minister 
• Capital of Tamilnadu 
• Capital of India 
• National animal 
2. New learning ability 
a)  4 unrelated words 
b) Story recall 
c) Visual memory 
d) Paired associate learning 
3. Judgements 
4. Similarities / dissimilarities 
a) Scooter / Car 
b) Bench / Table 
5. Calculation 
a) Verbal  – simple / complex 
b) Written  - simple / complex  
6. Abstract  Thinking 
 a) Proverb interpretation 
 b) Conceptual  series completion  
Lobar function evaluation: 
I. Frontal lobe function: 
• Initiation  defect 
• Weakness 
• Spasticity 
• Gaze preference 
• Saccades 
• Anti-saccades 
• Rhythmic tapping 
• Fluency 
• Perseveration 
• Impersistence 
• Alternate sequence  - Fist – ring – fist test 
- Fist – palm – fist test 
    - Luria’s triangle 
• Expressive aphasia 
• Cognition/plan/goal oriented actions 
• Mood 
• Personality 
• Behaviour 
• Insight 
• Apathy 
• Withdrawal 
• Social disinhibition 
• Aggressiveness 
• Outburst of anger 
• Gait apraxia 
• Unconcerned micturition 
• Release reflexes 
• Stroupe test 
II.  Parietal lobe function: 
a) Left parietal  
• Cortical sensory loss – Tactile localization/tactile 
discrimination 
• Ideational apraxia 
• Ideomotor apraxia 
• Alexia 
• Acalculia 
• Agraphia 
• Right – left orientation : Self / examiner 
b) Right parietal  
• Dressing apraxia 
• Constructional apraxia 
• Opto kinetic nystagmus 
• Visual orientation – cities in map 
• Hemineglect – visual / auditory / self 
Both sides 
 Inferior homonymous quadrantanopia 
III. Temporal lobe function: 
Bilateral  
• Superior homonymous quadrantanopia 
• Hallucinations:   
Auditory/Olfactory/Visual/Gustatory 
• Dreamy state with uncinate seizures 
• Emotional and behavioural changes 
• Delirium 
• Disturbance of time perception 
• Placidity 
• Korsakoff amnesic defect 
• Hypermetamorphosia 
• Kluver Bucy syndrome 
Left temporal: 
• Wernickes aphasia 
• Amnesia 
• Verbal memory 
• Dysnomia 
• Amnesic aphasia 
Right temporal: 
• Inability to judge spatial relations 
• Visual memory 
• Agnosia for sounds / music 
• Delirium 
• Prosody 
IV. Occipital lobe function: 
a) Bilateral 
• Contralateral homonymous hemianopia 
• Unformed hallucinations – Elementary / simple 
• Cortical blindness 
• Loss of color perception 
• Prosopagnosia 
• Simultanagnosia 
• Balint syndrome (optic ataxia,  oculomotor apraxia, 
simultanagnosia) 
b) Left occipital 
• Color anomia 
• Visual object agnosia : Apperceptive / Associative 
• Alexia 
c) Right occipital: 
• Metamorphosia 
• Topographic memory 
• Visual orientation 
Cranial nerves examination: 
Spiromotor exam: Bulk/Tone/Power/DTR/ 
Involuntary movements 
Sensory system evaluation : Pain, Touch, temp, vibration and joint  
position sense. 
Romberg sign 
Extra pyramidal system : Rigidity/Involuntary  movement 
(tremor,chorea,dystonia)  
Cerebellum: 
Spine and cranium: 
Meningeal signs: 
Gait: 
 
 
 
 
 
 
 
 
 
 
 
S.No Age Sex Education OccupationMarital statHIV duratioART duratiobase line C Latest CD4
1 39 1 5 1 4 15 14 39 129
2 37 1 7 7 4 120 26 179 247
4 40 1 7 2 1 39 39 108 237
6 36 1 8 2 1 66 60 216 718
9 37 1 8 1 4 15 1 350 298
12 34 1 4 2 1 72 2 377 622
13 32 1 5 2 1 48 1 284 104
14 34 1 8 2 4 60 12 649 613
20 38 1 5 2 1 18 18 215 237
22 39 1 3 2 1 75 75 128 414
24 50 1 4 1 4 36 36 148 833
31 27 1 5 2 1 51 48 286 722
33 36 1 8 1 4 48 48 112 280
34 43 1 5 1 4 39 39 124 328
36 40 1 7 2 1 48 48 37 263
39 45 1 5 1 4 36 36 160 242
40 49 1 5 1 4 46 46 180 395
44 32 1 10 1 1 51 48 360 654
45 26 1 8 2 1 48 48 94 420
46 35 1 9 1 1 42 42 142 576
47 37 1 8 1 1 48 48 160 734
48 35 1 9 2 1 48 48 140 219
49 55 1 5 2 1 39 38 180 339
50 30 1 10 2 1 72 70 163 791
3 59 2 3 6 4 48 24 255 253
5 49 2 12 1 1 21 20 58 194
7 40 2 3 1 1 72 36 184 104
8 29 2 5 3 2 8 6 189 189
10 36 2 4 1 1 72 72 56 321
11 42 2 5 1 1 12 12 204 484
15 48 2 4 4 1 3 1 87 87
16 42 2 5 5 1 72 72 198 119
17 36 2 10 4 3 72 48 211 73
18 38 2 4 1 1 10 9 134 264
19 42 2 8 1 1 30 30 52 312
21 48 2 5 1 1 3 2 68 68
23 27 2 10 3 1 12 12 209 261
25 38 2 3 1 1 40 16 234 155
26 27 2 15 1 2 27 3 196 134
27 34 2 7 1 1 60 60 172 402
28 43 2 10 1 1 36 36 117 950
29 44 2 8 1 1 40 40 56 315
30 41 2 7 1 1 36 36 56 166
32 41 2 8 1 1 48 48 150 160
35 44 2 10 1 1 37 33 322 156
37 36 2 9 1 1 48 48 116 192
38 45 2 10 1 1 48 48 34 218
41 40 2 8 1 1 42 36 442 232
42 39 2 8 1 1 52 52 95 142
43 49 2 10 1 1 48 48 39 200
STAGE ART REG attention‐DDB Vigilance Go‐No‐Go Spell backwSerial subtrLan‐spon spFLUENCY
III 2 2 2 2 2 2 2 1 1
I 2 2 2 2 2 2 2 1 1
III 3 2 2 2 2 2 2 1 1
II 1 2 2 2 2 2 2 1 1
III 5 1 1 1 1 1 1 1 1
I 1 1 1 1 1 1 1 1 1
II 2 1 1 1 1 1 1 1 1
III 2 1 1 1 1 1 1 1 1
I 1 2 2 2 2 2 2 1 1
I 1 2 2 2 2 2 2 1 1
I 1 2 2 2 2 2 2 1 1
I 2 1 1 1 1 1 1 1 1
IV 1 1 1 1 1 1 1 1 1
I 1 1 1 1 1 1 1 1 1
III 6 2 2 2 2 2 2 1 1
III 4 2 2 2 2 2 2 1 1
III 8 2 2 2 2 2 2 1 1
I 7 1 1 1 1 1 1 1 1
I 7 1 1 1 1 1 1 1 1
III 2 2 2 2 2 2 2 1 1
I 2 2 2 2 2 2 2 1 1
II 1 1 1 1 1 1 1 1 1
I 1 1 1 1 1 1 1 1 1
I 1 2 2 2 2 2 2 1 1
I 1 2 2 2 2 2 2 1 1
III 3 1 1 1 1 1 1 1 1
III 3 2 2 2 2 2 2 1 1
II 1 1 1 1 1 1 1 1 1
III 1 2 2 2 2 2 1 1 1
I 1 2 2 2 2 2 2 1 1
III 1 2 2 2 2 2 2 1 1
II 1 2 2 2 2 2 2 1 1
II 1 1 1 1 1 1 1 1 1
II 1 2 2 2 2 2 2 1 1
III 2 1 1 1 1 1 1 1 1
III 1 1 1 1 1 1 1 1 1
III 4 1 1 1 1 1 1 1 1
I 1 2 2 2 2 2 2 1 1
I 1 2 2 2 2 2 2 1 1
III 1 2 2 2 2 2 2 1 1
III 9 2 2 2 2 2 2 1 1
IV 3 2 2 2 2 2 2 1 1
III 2 2 2 2 2 2 2 1 1
III 2 2 2 2 2 2 2 1 1
I 1 2 2 2 2 2 2 1 1
III 7 1 1 1 1 1 1 1 1
III 2 2 2 2 2 2 2 1 1
III 1 1 1 1 1 1 1 1 1
III 1 2 2 2 2 2 2 1 1
III 8 1 1 1 1 1 1 1 1
COMPREHEREPETITIONNAMING READING WRITING SPELLING COPYING MEMORY‐I RECENT M REMOTE M
1 1 1 1 1 1 2 2 1 1
1 1 1 1 1 1 2 2 1 1
1 1 1 1 1 1 1 2 1 1
1 1 1 1 1 1 1 2 1 1
1 1 1 1 1 1 1 2 2 1
1 1 1 1 1 1 1 1 1 1
1 1 1 1 1 1 1 1 1 1
1 1 1 1 1 1 1 1 2 1
1 1 1 1 1 1 1 2 2 1
1 1 1 1 1 1 1 2 2 1
1 1 1 1 1 1 1 2 2 1
1 1 1 1 1 1 1 2 2 1
1 1 1 1 1 1 1 2 1 1
1 1 1 1 1 1 1 2 1 1
1 1 1 1 1 1 2 2 1 1
1 1 1 1 1 1 1 2 1 1
1 1 1 1 1 1 1 2 1 1
1 1 1 1 1 1 1 1 1 1
1 1 1 1 1 1 1 1 1 1
1 1 1 1 1 1 1 1 1 1
1 1 1 1 1 1 2 2 1 1
1 1 1 1 1 1 2 2 1 1
1 1 1 1 1 1 1 2 2 1
1 1 1 1 1 1 1 1 1 1
1 1 1 1 1 1 1 2 2 1
1 1 1 1 1 1 1 1 1 1
1 1 1 1 1 1 1 1 2 1
1 1 1 1 1 1 1 1 1 1
1 1 1 1 1 1 1 2 1 1
1 1 1 1 1 1 1 2 2 1
1 1 1 1 1 1 1 2 2 1
1 1 1 1 1 1 1 2 2 1
1 1 1 1 1 1 1 1 1 1
1 1 1 1 1 1 2 1 2 1
1 1 1 1 1 1 1 1 1 1
1 1 1 1 1 1 1 1 2 1
1 1 1 1 1 1 1 2 1 1
1 1 1 1 1 1 1 2 2 1
1 1 1 1 1 1 2 1 1 1
1 1 1 1 1 1 1 2 1 1
1 1 1 1 1 1 1 1 1 1
1 1 1 1 1 1 1 1 1 1
1 1 1 1 1 1 1 2 1 1
1 1 1 1 1 1 1 2 1 1
1 1 1 1 1 1 1 1 1 1
1 1 1 1 1 1 1 1 1 1
1 1 1 1 1 1 1 2 1 1
1 1 1 1 1 1 1 1 1 1
1 1 1 1 1 1 2 1 1 1
1 1 1 1 1 1 1 2 2 1
COGNITIONFUND GK NLA JUDGMENTSIMILA/DISCALCU ABSTRACT  FR‐WEAKN F‐ANTISACCFLUENCY
1 1 1 1 1 2 1 1 2
1 1 1 1 1 2 1 1 1
1 1 1 1 1 1 1 1 1
1 1 1 1 1 1 1 1 1
1 1 1 1 1 1 1 1 1
1 1 1 1 1 1 1 1 1
1 1 1 1 1 1 1 1 2
1 1 1 1 1 1 1 1 1
1 1 1 1 1 1 1 1 1
1 1 1 1 1 1 1 1 1
1 1 1 1 1 1 1 1 1
1 1 1 1 1 1 1 1 1
1 1 1 1 1 1 1 1 1
1 1 1 1 1 1 1 1 2
1 1 1 1 1 2 1 1 2
1 1 1 1 1 1 1 1 1
1 1 1 1 1 1 1 1 1
1 1 1 1 1 1 1 1 1
1 1 1 1 1 1 1 1 1
1 1 1 1 1 1 1 1 1
1 1 1 1 1 2 1 1 1
1 1 1 1 1 1 1 1 1
1 1 1 1 1 1 1 1 1
1 1 1 1 1 1 1 1 2
1 1 1 1 1 1 1 1 2
1 1 1 1 1 1 1 1 1
1 1 1 1 1 2 1 1 1
1 1 1 1 1 1 1 1 1
1 1 1 1 1 1 1 1 1
1 1 1 1 1 2 1 1 1
1 1 1 1 1 1 1 1 1
1 1 1 1 1 1 1 1 1
1 1 1 1 1 1 1 1 1
1 1 1 1 1 2 1 1 1
1 1 1 1 1 2 1 1 1
1 1 1 1 1 1 1 1 1
1 1 1 1 1 1 1 1 1
1 1 1 1 1 1 1 1 1
1 1 1 1 1 2 1 1 1
1 1 1 1 1 2 1 1 1
1 1 1 1 1 1 1 1 1
1 1 1 1 1 2 1 1 1
1 1 1 1 1 1 1 1 1
1 1 1 1 1 1 1 1 1
1 1 1 1 1 1 1 1 1
1 1 1 1 1 1 1 1 1
1 1 1 1 1 2 1 1 1
1 1 1 1 1 1 1 1 1
1 1 1 1 1 2 1 1 1
1 1 1 1 1 1 1 1 1
PERSEVERAIMPERSISTEALTER SEQ BROCA APHPERSONALIBEHA CHANGAIT APRA UNCONCERRELEASE REPA‐TA LO
1 1 1 1 1 1 1 1 1 1
1 1 1 1 1 1 1 1 1 1
1 1 1 1 1 1 1 1 1 1
1 1 1 1 1 1 1 1 1 1
1 1 1 1 1 1 1 1 1 1
1 1 1 1 1 1 1 1 1 1
1 1 1 1 1 1 1 1 1 1
1 1 1 1 1 1 1 1 1 1
1 1 1 1 1 1 1 1 1 1
1 1 1 1 1 1 1 1 1 1
1 1 1 1 1 1 1 1 1 1
1 1 1 1 1 1 1 1 1 1
1 1 1 1 1 1 1 1 1 1
1 1 1 1 1 1 1 1 1 1
1 1 1 1 1 1 1 1 1 1
1 1 1 1 1 1 1 1 1 1
1 1 1 1 1 1 1 1 1 1
1 1 1 1 1 1 1 1 1 1
1 1 1 1 1 1 1 1 1 1
1 1 1 1 1 1 1 1 1 1
1 1 1 1 1 1 1 1 1 1
1 1 1 1 1 1 1 1 1 1
1 1 1 1 1 1 1 1 1 1
1 1 1 1 1 1 1 1 1 1
1 1 1 1 1 1 1 1 1 1
1 1 1 1 1 1 1 1 1 1
1 1 1 1 1 1 1 1 1 1
1 1 1 1 1 1 1 1 1 1
1 1 1 1 1 1 1 1 1 1
1 1 1 1 1 1 1 1 1 1
1 1 1 1 1 1 1 1 1 1
1 1 1 1 1 1 1 1 1 1
1 1 1 1 1 1 1 1 1 1
1 1 1 1 1 1 1 1 1 1
1 1 1 1 1 1 1 1 1 1
1 1 1 1 1 1 1 1 1 1
1 1 1 1 1 1 1 1 1 1
1 1 1 1 1 1 1 1 1 1
1 1 1 1 1 1 1 1 1 1
1 1 1 1 1 1 1 1 1 1
1 1 1 1 1 1 1 1 1 1
1 1 1 1 1 1 1 1 1 1
1 1 1 1 1 1 1 1 1 1
1 1 1 1 1 1 1 1 1 1
1 1 1 1 1 1 1 1 1 1
1 1 1 1 1 1 1 1 1 1
1 1 1 1 1 1 1 1 1 1
1 1 1 1 1 1 1 1 1 1
1 1 1 1 1 1 1 1 1 1
1 1 1 1 1 1 1 1 1 1
GRAPHEST STEREOGN IDE APRA IDEOMO APDRES APR CONS APRAOKN HEMINEGL ALEXIA ACALCULIA
1 1 1 1 1 2 1 1 1 2
1 1 1 1 1 2 1 1 1 2
1 1 1 1 1 1 1 1 1 1
1 1 1 1 1 1 1 1 1 1
1 1 1 1 1 1 1 1 1 1
1 1 1 1 1 1 1 1 1 1
1 1 1 1 1 1 1 1 1 1
1 1 1 1 1 1 1 1 1 1
1 1 1 1 1 1 1 1 1 1
1 1 1 1 1 1 1 1 1 1
1 1 1 1 1 1 1 1 1 1
1 1 1 1 1 1 1 1 1 1
1 1 1 1 1 1 1 1 1 1
1 1 1 1 1 1 1 1 1 1
1 1 1 1 1 2 1 1 1 2
1 1 1 1 1 1 1 1 1 1
1 1 1 1 1 1 1 1 1 1
1 1 1 1 1 1 1 1 1 1
1 1 1 1 1 1 1 1 1 1
1 1 1 1 1 1 1 1 1 1
1 1 1 1 1 2 1 1 1 2
1 1 1 1 1 2 1 1 1 1
1 1 1 1 1 1 1 1 1 1
1 1 1 1 1 2 1 1 1 1
1 1 1 1 1 1 1 1 1 1
1 1 1 1 1 1 1 1 1 1
1 1 1 1 1 1 1 1 1 2
1 1 1 1 1 1 1 1 1 1
1 1 1 1 1 1 1 1 1 1
1 1 1 1 1 1 1 1 1 2
1 1 1 1 1 2 1 1 1 1
1 1 1 1 1 1 1 1 1 1
1 1 1 1 1 1 1 1 1 1
1 1 1 1 1 2 1 1 1 2
1 1 1 1 1 1 1 1 1 2
1 1 1 1 1 1 1 1 1 1
1 1 1 1 1 1 1 1 1 1
1 1 1 1 1 1 1 1 1 1
1 1 1 1 1 1 1 1 1 2
1 1 1 1 1 2 1 1 1 2
1 1 1 1 1 1 1 1 1 1
1 1 1 1 1 1 1 1 1 2
1 1 1 1 1 1 1 1 1 1
1 1 1 1 1 1 1 1 1 1
1 1 1 1 1 1 1 1 1 1
1 1 1 1 1 1 1 1 1 1
1 1 1 1 1 1 1 1 1 2
1 1 1 1 1 1 1 1 1 1
1 1 1 1 1 2 1 1 1 2
1 1 1 1 1 1 1 1 1 1
AGRAPHIA R/L ORIE INF QUADRWER APHA VERBAL MEAMNESIA DYSNOMIAVISUAL MEVISUOSPATHALLUC‐AU
1 1 1 1 1 2 1 1 1 1
1 1 1 1 1 2 1 1 1 1
1 1 1 1 1 2 1 1 1 1
1 1 1 1 1 2 1 1 1 1
1 1 1 1 1 1 1 1 1 1
1 1 1 1 1 1 1 1 1 1
1 1 1 1 1 1 1 1 1 1
1 1 1 1 1 1 1 1 1 1
1 1 1 1 1 2 1 1 1 1
1 1 1 1 1 2 1 1 1 1
1 1 1 1 1 2 1 1 1 1
1 1 1 1 1 2 1 1 1 1
1 1 1 1 1 2 1 1 1 1
1 1 1 1 1 2 1 1 1 1
1 1 1 1 1 2 1 1 1 1
1 1 1 1 1 2 1 1 1 1
1 1 1 1 1 2 1 1 1 1
1 1 1 1 1 1 1 1 1 1
1 1 1 1 1 1 1 1 1 1
1 1 1 1 1 1 1 1 1 1
1 1 1 1 1 2 1 1 1 1
1 1 1 1 1 2 1 1 1 1
1 1 1 1 1 2 1 1 1 1
1 1 1 1 1 1 1 1 1 1
1 1 1 1 1 2 1 1 1 1
1 1 1 1 1 1 1 1 1 1
1 1 1 1 1 1 1 1 1 1
1 1 1 1 1 1 1 1 1 1
1 1 1 1 1 2 1 1 1 1
1 1 1 1 1 2 1 1 1 1
1 1 1 1 1 2 1 1 1 1
1 1 1 1 1 2 1 1 1 1
1 1 1 1 1 1 1 1 1 1
1 1 1 1 1 1 1 1 1 1
1 1 1 1 1 1 1 1 1 1
1 1 1 1 1 1 1 1 1 1
1 1 1 1 1 2 1 1 1 1
1 1 1 1 1 2 1 1 1 1
1 1 1 1 1 1 1 1 1 1
1 1 1 1 1 2 1 1 1 1
1 1 1 1 1 1 1 1 1 1
1 1 1 1 1 1 1 1 1 1
1 1 1 1 1 2 1 1 1 1
1 1 1 1 1 2 1 1 1 1
1 1 1 1 1 1 1 1 1 1
1 1 1 1 1 1 1 1 1 1
1 1 1 1 1 2 1 1 1 1
1 1 1 1 1 1 1 1 1 1
1 1 1 1 1 1 1 1 1 1
1 1 1 1 1 2 1 1 1 1
HALL‐VIS HALL‐GUS HALL‐OLF SUP QUAD KORSO AMKLUVER BUCOLOR AGNVISU‐APPERVI‐ASS‐AG VISU‐ORI
1 1 1 1 1 1 1 1 1 1
1 1 1 1 1 1 1 1 1 1
1 1 1 1 1 1 1 1 1 1
1 1 1 1 1 1 1 1 1 1
1 1 1 1 1 1 1 1 1 1
1 1 1 1 1 1 1 1 1 1
1 1 1 1 1 1 1 1 1 1
1 1 1 1 1 1 1 1 1 1
1 1 1 1 1 1 1 1 1 1
1 1 1 1 1 1 1 1 1 1
1 1 1 1 1 1 1 1 1 1
1 1 1 1 1 1 1 1 1 1
1 1 1 1 1 1 1 1 1 1
1 1 1 1 1 1 1 1 1 1
1 1 1 1 1 1 1 1 1 1
1 1 1 1 1 1 1 1 1 1
1 1 1 1 1 1 1 1 1 1
1 1 1 1 1 1 1 1 1 1
1 1 1 1 1 1 1 1 1 1
1 1 1 1 1 1 1 1 1 1
1 1 1 1 1 1 1 1 1 1
1 1 1 1 1 1 1 1 1 1
1 1 1 1 1 1 1 1 1 1
1 1 1 1 1 1 1 1 1 1
1 1 1 1 1 1 1 1 1 1
1 1 1 1 1 1 1 1 1 1
1 1 1 1 1 1 1 1 1 1
1 1 1 1 1 1 1 1 1 1
1 1 1 1 1 1 1 1 1 1
1 1 1 1 1 1 1 1 1 1
1 1 1 1 1 1 1 1 1 1
1 1 1 1 1 1 1 1 1 1
1 1 1 1 1 1 1 1 1 1
1 1 1 1 1 1 1 1 1 1
1 1 1 1 1 1 1 1 1 1
1 1 1 1 1 1 1 1 1 1
1 1 1 1 1 1 1 1 1 1
1 1 1 1 1 1 1 1 1 1
1 1 1 1 1 1 1 1 1 1
1 1 1 1 1 1 1 1 1 1
1 1 1 1 1 1 1 1 1 1
1 1 1 1 1 1 1 1 1 1
1 1 1 1 1 1 1 1 1 1
1 1 1 1 1 1 1 1 1 1
1 1 1 1 1 1 1 1 1 1
1 1 1 1 1 1 1 1 1 1
1 1 1 1 1 1 1 1 1 1
1 1 1 1 1 1 1 1 1 1
1 1 1 1 1 1 1 1 1 1
1 1 1 1 1 1 1 1 1 1
TOPO MEMMETAMOR CONT H HEUNF VI HALCORTICAL BPROSOPO BALINT SYNSIMULT C R NERV MOTOR
1 1 1 1 1 1 1 1 1 1
1 1 1 1 1 1 1 1 1 1
1 1 1 1 1 1 1 1 1 1
1 1 1 1 1 1 1 1 1 1
1 1 1 1 1 1 1 1 1 1
1 1 1 1 1 1 1 1 1 1
1 1 1 1 1 1 1 1 1 1
1 1 1 1 1 1 1 1 1 1
1 1 1 1 1 1 1 1 1 1
1 1 1 1 1 1 1 1 1 1
1 1 1 1 1 1 1 1 1 1
1 1 1 1 1 1 1 1 1 1
1 1 1 1 1 1 1 1 1 1
1 1 1 1 1 1 1 1 1 1
1 1 1 1 1 1 1 1 1 1
1 1 1 1 1 1 1 1 1 1
1 1 1 1 1 1 1 1 1 1
1 1 1 1 1 1 1 1 1 1
1 1 1 1 1 1 1 1 1 1
1 1 1 1 1 1 1 1 1 1
1 1 1 1 1 1 1 1 1 1
1 1 1 1 1 1 1 1 1 1
1 1 1 1 1 1 1 1 1 1
1 1 1 1 1 1 1 1 1 1
1 1 1 1 1 1 1 1 1 1
1 1 1 1 1 1 1 1 1 1
1 1 1 1 1 1 1 1 1 1
1 1 1 1 1 1 1 1 1 1
1 1 1 1 1 1 1 1 1 1
1 1 1 1 1 1 1 1 1 1
1 1 1 1 1 1 1 1 1 1
1 1 1 1 1 1 1 1 1 1
1 1 1 1 1 1 1 1 1 1
1 1 1 1 1 1 1 1 1 1
1 1 1 1 1 1 1 1 1 1
1 1 1 1 1 1 1 1 1 1
1 1 1 1 1 1 1 1 1 1
1 1 1 1 1 1 1 1 1 1
1 1 1 1 1 1 1 1 1 1
1 1 1 1 1 1 1 1 1 1
1 1 1 1 1 1 1 1 1 1
1 1 1 1 1 1 1 1 1 1
1 1 1 1 1 1 1 1 1 1
1 1 1 1 1 1 1 1 1 1
1 1 1 1 1 1 1 1 1 1
1 1 1 1 1 1 1 1 1 1
1 1 1 1 1 1 1 1 1 1
1 1 1 1 1 1 1 1 1 1
1 1 1 1 1 1 1 1 1 1
1 1 1 1 1 1 1 1 1 1
SENSOR P N EPS CEREBELLUSPI&CRA B & BOWELANIMAL NATriad test AVLT 1 AVLT2
1 1 1 1 1 1 9 12 2 6
2 2 1 1 1 1 11 10 7 7
1 1 1 1 1 1 14 12 7 11
1 1 1 1 1 1 12 7 7 6
2 2 1 1 1 1 13 8 3 7
1 1 1 1 1 1 11 14 6 5
2 2 1 1 1 1 10 10 5 7
1 1 1 1 1 1 8 8 6 5
1 1 1 1 1 1 11 10 5 7
1 1 1 1 1 1 10 12 4 9
2 2 1 1 1 1 7 12 5 5
1 1 1 1 1 1 12 12 5 7
1 1 1 1 1 1 12 10 6 8
2 2 1 1 1 1 10 12 5 7
1 1 1 1 1 1 12 9 6 8
1 1 1 1 1 1 10 12 5 7
1 1 1 1 1 1 11 11 6 8
1 1 1 1 1 1 14 8 8 10
1 1 1 1 1 1 13 11 7 8
1 1 1 1 1 1 14 10 6 8
1 1 1 1 1 1 12 9 7 9
1 1 1 1 1 1 14 8 6 7
1 1 1 1 1 1 10 12 5 7
2 2 1 1 1 1 14 7 7 9
2 2 1 1 1 1 14 12 4 6
1 1 1 1 1 1 13 9 6 9
1 1 1 1 1 1 9 10 5 7
2 2 1 1 1 1 10 11 7 9
2 2 1 1 1 1 14 12 6 8
1 1 1 1 1 1 11 12 6 8
2 2 1 1 1 1 7 11 4 3
1 1 1 1 1 1 12 10 6 8
1 1 1 1 1 1 14 8 7 9
1 1 1 1 1 1 12 11 5 7
2 2 1 1 1 1 12 9 7 8
1 1 1 1 1 1 10 11 6 7
1 1 1 1 1 1 14 8 8 5
1 1 1 1 1 1 9 12 3 3
2 2 1 1 1 1 16 5 8 9
1 1 1 1 1 1 12 10 7 8
2 2 1 1 1 1 14 8 7 10
1 1 1 1 1 1 14 10 7 9
1 1 1 1 1 1 12 10 6 8
1 1 1 1 1 1 14 11 7 9
1 1 1 1 1 1 15 7 7 9
2 2 1 1 1 1 14 8 7 8
1 1 1 1 1 1 12 6 6 8
2 2 1 1 1 1 13 10 6 8
2 2 1 1 1 1 12 9 7 8
1 1 1 1 1 1 12 6 6 8
 
3 4 5 Total NC LIST B IR NC DR NC RAVEN MAMMSE Trial makin
6 11 9 34 3 5 6 18 22 75
7 9 8 38 2 6 6 17 23 90
10 12 11 51 5 7 8 13 22 120
8 10 11 42 4 4 5 28 25 135
10 9 10 39 3 5 4 15 24 95
5 8 7 31 2 4 5 14 21 120
8 10 9 39 4 3 5 20 25 90
7 6 7 31 2 4 4 13 28 65
8 10 10 40 3 3 3 22 30 70
8 9 11 41 2 3 3 25 26 210
8 9 7 34 3 4 4 18 15 105
8 8 9 37 3 4 4 18 23 80
9 11 10 44 4 6 6 22 27 70
8 8 9 37 2 4 6 20 23 85
8 10 9 41 3 5 7 22 26 70
8 9 9 38 3 4 6 18 24 75
8 10 9 41 3 6 5 20 25 70
10 11 12 51 5 9 8 28 29 40
9 11 10 45 3 6 7 24 27 65
10 10 11 45 4 9 8 22 26 60
11 12 12 51 6 7 7 26 29 50
9 9 10 41 3 8 7 22 26 70
7 8 8 35 3 3 4 18 23 85
10 11 12 49 5 6 7 26 29 50
7 9 8 34 2 4 4 17 20 85
12 11 13 51 6 8 8 36 28 48
8 10 9 39 3 5 5 11 21 120
10 11 9 46 4 5 6 16 22 105
9 9 10 42 3 4 5 18 25 90
9 9 11 43 3 5 5 19 26 80
7 6 7 27 2 3 4 18 18 90
7 9 10 40 4 4 5 23 24 75
8 10 11 45 5 5 6 29 28 55
7 8 7 34 2 3 4 26 30 85
10 9 11 45 4 5 5 27 30 50
9 6 6 34 4 3 4 17 22 75
7 9 9 38 4 4 6 10 29 30
3 3 4 16 2 2 2 5 25 205
10 9 10 53 5 7 9 30 30 60
10 9 10 44 4 4 6 24 27 70
9 11 12 49 4 7 8 23 29 65
10 9 11 46 5 6 6 21 27 65
9 8 10 41 3 5 6 20 25 70
11 10 10 47 3 5 7 23 26 60
9 11 11 47 4 6 8 26 28 50
10 11 10 46 5 6 8 21 25 55
9 11 11 45 4 5 7 20 25 60
9 11 11 45 4 5 7 22 26 60
7 9 9 40 3 6 6 21 25 70
8 10 9 41 4 4 5 23 26 55
 DVT‐TT‐‐ERDVT‐ERRORDSST‐TT‐ERDSST‐ER
1560 0 1080 2
780 2 420 2
1020 45 1680 15
480 18 360 3
960 3 480 0
900 6 840 12
1200 11 1440 21
720 2 600 1
1020 7 750 2
2400 2 1800 28
1800 4 1200 11
1260 4 720 4
960 5 520 0
1050 12 780 3
1020 6 540 0
1080 4 720 2
1020 6 750 1
1020 2 600 0
960 6 720 0
900 8 780 0
1020 4 660 0
930 7 520 0
1080 12 900 2
900 2 480 0
900 45 1200 20
300 7 180 0
960 8 840 7
420 7 300 2
1020 17 840 4
1020 14 720 2
2580 20 1500 7
1020 8 780 5
660 0 420 0
960 12 650 4
840 4 600 0
1860 12 1020 3
1320 0 720 0
2260 5 1320 6
930 6 290 0
1020 6 330 2
780 8 300 0
960 10 480 0
1020 8 650 2
900 3 480 0
900 2 300 0
940 5 480 0
1020 2 600 0
960 10 630 0
1020 8 660 0
1140 4 620 0
